

厚生労働科学研究費補助金  
地球環境保健課題推進研究事業  
( H29-地球環境一般002)

我が国の世界保健総会等における効果的なプレゼンスの確立に関する研究

平成31年度 総括・分担研究報告書

代表研究者 渋谷健司

令和2年度 (2020)年7月

# 目次

## I. 総合研究報告

我が国の世界保健総会等における効果的なプレゼンスの確立に関する研究

研究代表者 渋谷健司 東京大学大学院医学系研究科 国際保健政策学教室 教授

## II. 分担研究報告

1. Context and challenges of Japan's health system

研究分担者 坂元清香 東京大学大学院医学系研究科 国際保健政策学教室 特任研究員

研究協力者 渋谷健司 東京大学大学院医学系研究科 国際保健政策学教室 教授

2. Global Health Diplomacy Workshop

研究分担者 明石秀親 国立国際医療研究センター 連携協力部長

三好由明 国立国際医療研究センター 人材開発部長

坂元清香 東京大学大学院医学系研究科 国際保健政策学教室 特任研究員

研究協力者 渋谷健司 東京大学大学院医学系研究科 国際保健政策学教室 教授

野村周平 東京大学大学院医学系研究科 国際保健政策学教室 助教

## III. 参考資料

資料1 Mikkelsen L, Iburg, KM, Adair T, Fürst T, Hegnauer M, von der Lippe E, Moran L, Nomura S, Sakamoto H, Shibuya K, Wengler A, Willbond S, Wood P, Lopez AD. **Assessing the quality of cause of death data in six high-income countries: Australia, Canada, Denmark, Germany, Japan and Switzerland.** Int J Public Health. 2020 Jan; 65, 17–28.

資料2 Global Health Diplomacy Workshop in Japan, 2019 Agenda

総合研究報告書

主任研究

渋谷健司

東京大学大学院医学系研究科国際保健政策学教室 教授

研究要旨

2016年のG7伊勢志摩サミット・神戸保健大臣会合では、議長国である日本が中心となり世界を巻き込んだ政策研議が行われ、グローバルヘルス分野における我が国のプレゼンスが確実に示された。G7を終えた現在も、我が国が主導してグローバルヘルスの課題を前進させ、主要会合において効果的に議論を先導する役割を果たす必要がある。初年度はG7伊勢志摩サミットのプロセスを通じて我が国がグローバルヘルスにどのように貢献したかについて分析を行った。加えて、日本がグローバルヘルス分野優先領域として定めているユニバーサル・ヘルス・カバレッジ(UHC)については、現在世界的にも大きな政策目標となっており、我が国の知見がアジア諸国を中心とした発展途上国から求められている。また、低成長と少子高齢化の中で多くの課題が噴出し、我が国がどのように対応していくかが世界の注目を集めている。これら課題を中心的に、我が国の保健医療制度に関する分析を行い、論文や書籍を発表してきた。

また、我が国の保健医療制度の現状と課題を理解する上で、我が国の疾病構造とその負担を的確に理解することは必要不可欠である。その分析に用いられる主要死因のデータの正確性は極めて重要であることは以前から指摘されており、今年度は、メルボン大学の協力の元、日本と他に死亡関連情報システムが整っている5カ国を対象にデータの質検証を行なった。

なお日本・諸外国共にUHCを含めた今後のグローバル・ヘルスの推進には人材育成が急務であることから、本研究ではタイ公衆衛生省等と協力し、ワークショップの開催並びに人材開発プログラムの策定を実施した。

これらの研究から得られた知見は、今後UHC達成を目指す各国にとって、社会経済状況や疾病構造の変化とそれが保健医療政策に及ぼす影響についての対処を講じるために有用となるとともに、我が国が国際会議等の場でUHCの議論に参画する際の基盤となる知識を提供するものでもある。

## A. 研究目的

2016年のG7伊勢志摩サミット・神戸保健大臣会合では、議長国である日本が中心となり世界を巻き込んだ政策形成が行われ、グローバルヘルス分野における我が国のプレゼンスが確実に示された。G7を終えた現在も、我が国が主導してグローバルヘルスの課題を前進させ、主要会合において効果的に議論を先導する役割を果たす必要がある。しかし、これまで、国際的議論の場における戦略的介入に関する系統的な分析は我が国では行われていない。

政策分析と定量的分析の2つのアプローチを有機的に用いて、今後のWHO主要会合において我が国がより効果的にイニシアチブを取るための方策を提案する。先のG7に向けて我が国の国際保健外交政策の現場に参画し政策指針をまとめた実績ある研究者が、政府及びWHO関係者らと共同で分析を行うために、成果が確実に期待できる。さらに、特に若手の政府人材を含む将来の国際保健人材に対し会議等でのスピーチや交渉、ファシリテーションの能力開発、効果的・戦略的介入のためのワークショップ開催を行うとともに、政府代表団に同行し実際の各種会合において直接的な技術支援も提供する。

最終年度に当たる平成31年度はこれまでの学際的な研究活動を集大成し、WHO総会等における効果的なイニシアチブの取り方に関する戦略提言をまとめる。学術誌への論文発表も行い、また本研究班からの成果は特

に国内外の学会や会議にて積極的に発表する。成果はすべて一般公開し、広く市民社会への還元を図る。

本研究の成果は、我が国のグローバルヘルスにおけるプレゼンスと知的貢献の強化に直接資するものであり、我が国の国際保健外交戦略とも合致した内容である。主な成果物は、政府へ向けたWHO主要会合のための戦略提言書、学術論文、効果的・戦略的介入のためのマニュアル開発とワークショップ開催である。若手人材の能力開発や政府代表団への技術支援は、我が国における保健医療政策分析人材の知的・人的貢献のプールを作ることも視野に入れている。

## B. 研究方法

平成31年度は主に以下を実施する。

平成31年度：1. 班会議（4月：東京）：前年を踏まえ、今年度の活動予定や分担等について関係者間で議論を行う。なお、全体会議は年2回開催する。2. WHO総会事前勉強会（4月-5月：東京）：5月下旬に開催される第72回WHO総会に備え、国内外の専門家を招聘し主要議題に関する事前勉強会を開催する。3. 国際保健外交ワークショップ（5月：タイ）：国際保健政策外交ワークショップに日本側講師として参加する。4. 研究の中間報告会（9月）：2.及び3.を踏まえ、年度後半の活動計画について見直しを行うとともに、各分担研究者より研究の経過報告を行う。分析を年度内に完了し、最終レポートの草稿を作成する。5. 国際保健外交ワークショップ日本（東京）：タイから専門家を招聘し保健関連会合における両国のプレゼンスや貢献に係る課題を中心に

情報交換を行う。また会議における政府関係者のスピーチや交渉、ファシリテーションの能力開発を目的としたワークショップを開催する。

### C. 研究結果

初年度は G7 伊勢志摩サミットのプロセスを通じて我が国がグローバルヘルスにどのように貢献したかについて分析を行った。加えて、日本がグローバルヘルス分野優先領域として定めているユニバーサル・ヘルス・カバレッジ (UHC) については、現在世界的にも大きな政策目標となっており、我が国の知見がアジア諸国を中心とした発展途上国から求められている。また、低成長と少子高齢化の中で多くの課題が噴出し、我が国がどのように対応していくかが世界の注目を集めている。これら課題を中心に、我が国の保健医療制度に関する分析を行い、論文や書籍を発表してきた。

また、我が国の保健医療制度の現状と課題を正確に理解する上で重要視されている主要死因データの的確性について、メルボン大学の協力の元で検証を行なった。国の疾病構造や主要死因を分析する上で、死因として不適切または使用不能な主要死因は、比較研究を行なった 6 カ国の死因データのうち 18% であり、日本では 25% であった。情報が不十分な死因データは 6 カ国全体の 8% を占めており、日本では 11% であった。例えば、日本の 70 歳以上の死因のうち、17% は「高齢」によるものと診断されていた。日本の死因データの約 1/4 が不適切で

あることは、我が国の疾病負荷を正しく把握し、適切な保健医療制度及び投資をする上で大きな課題となりうる。これらの結果は International Journal of Public Health で発表した。

なお、日本・諸外国共に UHC を含めた今後のグローバル・ヘルスの推進のために、本分野における人材育成が急務であり、本研究ではタイ公衆衛生省等と協力し、ワークショップの開催並びに人材開発プログラムの策定を実施した。本年度のワークショップでは、25 名の参加があった他、タイの公衆衛生省と外務省及び中国から国際保健の有識者を招聘し、研修全般に渡り支援を受けた。

### D. 考察

1) 本研究の成果は、我が国のグローバルヘルスにおけるプレゼンスと知的貢献の強化に直接資する。つまりそれは、国際貢献という観点のみならず、我が国の国際保健外交戦略とも合致した内容である。2) 本研究の主な成果物としては、政府へ向けた WHO 主要会合のための戦略提言書及び学術論文のみならず、効果的・戦略的介入のためのマニュアル開発とワークショップ開催である。これまで重点的に分析されてこなかった我が国の WHO 等会合におけるプレゼンスや優位性、弱点を包括的に分析し、保健医療研究者と政策決定者の連携をとりながら、より戦略的・効果的なイニシアチブの取り方を提案する。本研究を通して得られた手法や成果はすべて一般公開し、広く

社会へ還元していく。3)本研究では、若手の政府人材を含む将来の国際保健人材に対し会議等でのスピーチや交渉、ファシリテーションの能力開発を行うとともに、我が国における保健医療政策分析人材の知的・人的貢献のプールを作ることも視野に入れる。

#### E. 結論

2016年G7伊勢志摩サミット及び関連会合を通じて我が国はグローバルヘルスを積極的に牽引してきた。とりわけ、現在 グローバルヘルスにおける最重要課題であるUHCへの貢献は大きい。我が国では1961年に国民皆保険制度を達成し、以降人口動態や疾病構造の変化を踏まえて数々の制度改革を繰り返し、現在では世界有数の健康目標を達成している。一方で、アジア地域の多くの国ではまだUHC達成の途上であり、我が国がこれまで経験してきた成功例・失敗例の双方が有用となりうる。我が国が今後も引き続き当効野においてリーダーシップを発揮するとともに、UHC以外の重要課題（Health Security、NCDs等）においても同様のリーダーシップを発揮することが望まれる。

#### F. 健康危険情報

特になし

#### G. 研究発表

##### 1. 論文発表

Mikkelsen L, Iburg, KM, Adair T, Fürst T, Hegnauer M, von der Lippe E, Moran L, Nomura S, Sakamoto H, Shibuya K, Wengler A, Willbond S, Wood P, Lopez AD. **Assessing the quality of cause of death data in six high-income**

**countries: Australia, Canada, Denmark, Germany, Japan and Switzerland.** Int J Public Health. 2020 Jan; 65, 17–28.

##### 2. 学会発表

特になし

#### H. 知的財産権の出願・登録状況

( 予定を含む。 )

##### 1. 特許取得

特になし

##### 2. 実用新案登録

特になし

##### 3. その他

特になし



厚生労働科学研究費補助金(地球保健政策課題推進研究事業)

「我が国の世界保健総会等における効果的なプレゼンスの確立に関する研究」(H29-地球保健一般002)

平成30年度分研究報告書

Context and challenges of Japan's health system

研究担者 坂元清香

東京大学大学院医学系研究科 国際保健政策学教室 特任研究員

研究協力者

渋谷健司

東京大学大学院医学系研究科 国際保健政策学教室 教授

#### 研究要旨

UHC(すべての人に基本的な保健サービスを支払い可能な価格で普及させること)が大きな政策目標となったグローバルヘルス分野において、我が国の知見がアジア諸国を中心とした発展途上国から求められている。また、低成長と少子高齢化の中で多くの課題が噴出し、我が国がどのように対応していくかが世界の注目を集めている。UHCはWHO総会をはじめとして各種国際会議にて必出の議題となっており、また2019年にはUHCに関する国連ハイレベル会合の開催もされ、UHCに関する議論は今後も盛り上がることが予想される。本研究は、WHO総会等の主要会合における日本のプレゼンス向上を大目標に掲げるものであるが、とりわけ、G7伊勢志摩サミット以降日本が牽引し、また今後国際的にも議論が盛り上がるであろうUHCに焦点を当て、UHCを推進する上で我が国の比較優位性を抽出するものである。主な研究目的は1) WHO Asia-Pacific Health Observatory(APO)の枠組みを活用し、我が国の保健医療制度の現状と課題及び将来像を、実証的かつ包括的に分析すること、2) Global Burden of Disease(GBD)の枠組みを用い、人口動態や疾病構造の劇的な変化が都道府県レベルでどのような影響を及ぼしているかを明らかにすることで、UHC達成に必要な不可欠な格差解消への示唆を得ることである。今年度は2) Global Burden of Disease(GBD)の枠組みを用いて保健医療制度の現状と課題を正確に理解する上で重要とされている主要死因データの的確性について、メルボン大学の協力の元で検証を行なった。国の疾病構造や主要死因を分析する上で、死因として不適切または使用不能な主要死因は、比較研究を行なった6カ国の死因データのうち18%であり、日本では25%であった。情報が不十分な死因データは6カ国全体の8%を占めており、日本では11%であった。例えば、日本の70歳以上の死因のうち、17%は「高齢」によるものと診断されていた。日本の死因データの約1/4が不適切であることは、我が国の疾病負荷を正しく把握し、適切な保健医療制度及び投資をする上で大きな課題となりうる。これらの結果はInternational Journal of Public Healthで発表した。



## A . 研究目的

The Global Burden of Disease (GBD) studies have documented remarkable improvements in health that have occurred during the last decade, but also how unevenly health outcomes are distributed between and within populations. A recent study has raised concerns that adult death rates for many diseases have plateaued and, in some cases, increased, including in high-income countries (Roth et al. 2018). Subnational data have demonstrated surprising health inequality in some countries with well-developed health systems (AIHW 2018; Chammartin et al. 2016; Mahapatra et al. 2007; Roth and Dwyer-Lindgren 2017). To be able to monitor such health trends and the impact of interventions accurately, valid, reliable, regular and up-to date national mortality and morbidity data are essential (Lopez 2013; Shibuya 2006).

The global health goals and accountability for their achievements have led to significant interest in monitoring data quality and to the development of summary indicators such as the Vital Statistics Performance Index (VSPI) which measures the quality and timeliness of available mortality data (Mikkelsen et al. 2015; Philips et al. 2014). However, to be able to determine what actions need to be taken to improve statistical outputs, a more comprehensive review of the data is needed to better understand the main data quality issues and their origins. The usual research methodology to assess the accuracy of causes of death (COD)

is to undertake an independent review of a sample of medical records and compare the records with the cause(s) written on the death certificate (Alpe'rovitch et al. 2009), or to compare the clinical COD to an autopsy-based COD (Schdev 2001). Such studies, however, are complex and expensive to carry out and usually conducted in only one or a handful of hospitals. The findings have often indicated that even in countries with well-functioning civil registration and vital statistics (CRVS) systems, the quality of the medical certification is not as good as might be expected (Rampatige et al. 2014; Adair et al. 2019). Accuracy in COD certification is likely to be a growing issue in countries experiencing significant population ageing, in particular related to dementia and multiple chronic conditions that make accurate and consistent certification more challenging (Naghavi et al. 2010).

Within this context, it is crucial to be able to understand how well national mortality data systems of high-income countries are performing, given the expectations for them. To address this issue, we assessed the certification specificity and policy utility of the national COD data from six high-income countries with highly developed health information systems: Australia, Canada, Denmark, Germany, Japan and Switzerland.

## B . 研究方法

Medical certification of death is a requirement in all the countries included in this study. Certifiers, mostly physicians and special health care

providers, are asked to complete a medical death certificate indicating what was, in their opinion, the sequence of morbid events leading to death. Subsequently, the information provided on the death certificate is coded by trained coders, applying the International Statistical Classification of Diseases and Related Health Problems (ICD) and its rules for COD coding, and compiled by health or statistical authorities (WHO 2016).

National data on population and COD coded to ICD-10, by age group and sex, were provided by Australia, Canada and Germany for 2016 and downloaded from the World Health Organization (WHO) website for Denmark, Japan and Switzerland for 2015 (WHO 2019). To evaluate the data sets, the ANACONDA tool (see Annex 1, Mikkelsen et al. 2020) that assesses the quality of national and subnational COD data was used.

The accuracy of the COD output is dependent on physicians providing enough information on the death certificate for coders to select and code the underlying COD. When this process is not completed correctly, the COD output may contain codes labelled “garbage” codes (Murray and Lopez 1996) because they are of little or no use for policy decision-making. Historically, “garbage” codes are defined as causes that cannot or should not be an underlying cause of death (Naghavi et al. 2010). The term, despite its inelegance, has now been an integral part of the literature for more than a quarter of a century.

Since ANACONDA uses the same concept and definition for these codes, we have retained the original terminology in the paper.

To provide additional insight into the provenance and policy implications of these codes, ANACONDA classifies garbage codes into two distinct typologies. In the first typology, garbage codes are grouped into five categories based on ICD concepts:

- Category 1: Codes relating to symptoms, signs and ill-defined conditions (most drawn from ICD Chapter XVIII); e.g. R99 Other ill-defined and unspecified causes of mortality).
- Category 2: Codes that are not valid as an underlying cause of death (e.g. T12 Fracture of lower limb).
- Category 3: Codes that represent intermediate causes of death (e.g. I50 Heart failure).
- Category 4: Codes that represent immediate causes of death (e.g. I46 Cardiac arrest).
- Category 5: Codes that represent insufficiently specified causes within ICD chapters or within a larger disease category (e.g. D48.9 Neoplasm of uncertain or unknown behaviour, unspecified).

ANACONDA also includes a second typology, which focuses much more on the potential impact that garbage codes might have on misguiding policy and planning (Naghavi 2020). In this typology, garbage codes are grouped into four impact levels, from “very high” (level 1) to “low” (level 4):

- Very high (level 1): This highest level represents causes for which the true underlying cause could be a communicable or non-communicable disease, or the result of an injury (e.g. septicaemia).
- High (level 2): These are causes with substantial negative impact, but where the true cause is mostly limited to one of the three broad cause groups mentioned above, e.g. essential (primary) hypertension that can be due to different non-communicable diseases.
- Medium (level 3): CODs classified to the third level are only considered to have a medium negative impact for policy since, in this case, the underlying cause is likely to be within the same ICD chapter (e.g. unspecified cancer).
- Low (level 4): Causes classified as having low negative impact are those where the true underlying cause is likely to be confined to a single disease or injury group, such as unspecified stroke or unspecified pneumonia.

These “impact-level” categories can be further grouped into those that provide no or little useful information about the true underlying cause (levels 1–3), which we therefore refer to as “unusable”, and those in level 4 that provide sufficient information to guide public health interventions but not for research and technology development (Naghavi et al. 2010). We refer to the latter as “insufficiently specified” causes as they impair evidence-based health policy processes only to a limited extent. However, correcting these becomes increasingly important if our health information systems are to

appropriately guide research, hospital financial flows, resource allocation and healthcare strategies (WHO 2019). This is likely to be particularly of relevance in countries with ageing populations where most deaths happen in hospitals, primarily from non-communicable diseases.

In countries where unusable codes are assigned to a large proportion of all deaths, the true COD distribution can be seriously distorted and thereby mislead policy dialogue. This is particularly serious when garbage codes are common among the leading causes of death. From the input data, ANACONDA automatically provides a listing of the top-20 COD for males and females and indicates those that are considered to be unusable (levels 1–3) or insufficiently specified (level 4). The higher the number of these codes and the higher their ranking, the greater their impact on misinforming policy is going to be.

The relationship between age and garbage codes is also investigated with the ANACONDA tool to verify whether they are particular to certain age groups. Furthermore, given that some differences might exist in population age structure between the six countries, we used the global proportion of deaths by age from the latest Global Burden of Disease Study as the standard (Murray et al. 2018) to age-standardize the garbage codes in the countries.

Data completeness, a key indicator of data quality, was not considered, given that all six countries have civil registration systems that register all deaths. The focus of our data quality analysis therefore was limited to the levels, patterns and distribution of garbage codes.

### C . 研究結果

Despite the six countries being from three different geographic regions—Europe, Asia-Pacific and North America—their health systems and socio-economic indicators are comparable (Annex 2 Table 1S). Life expectancy varies from 78 to 81 years for males and 83 to 87 years for females, with all having very low child mortality rates of 2–5 per 1000 live born. The total fertility rates and proportion of 65 years and above indicate that Australia and Canada have somewhat younger populations than Denmark, Germany, Japan and Switzerland. Switzerland, with a private health insurance system, spends significantly more money on health care per person than the other countries. The Socio-Demographic Index (SDI) (Wang et al. 2016), a measure of national development based on income, education and fertility, is high for all countries, especially Denmark, while Germany and Denmark are doing slightly less well than the others on the Health Access and Quality Index (HAQ). The VSPI(Q), a measure of the overall quality of mortality data calculated by ANACONDA, is the highest in Australia and the lowest in Japan.

In the six countries studied, the average proportion of unusable codes (levels 1–3) was 18%, being slightly lower (14%) in Australia and Canada, while higher in Japan, where one in four deaths is assigned an unusable cause (Table 1). Insufficiently specified codes (level 4), in addition, averaged 8%, varying from 6% in Switzerland to 11% in Japan. Three of the most common CODs in the insufficiently specified group are pneumonia, stroke and diabetes all unspecified. For these CODs, the certifier could have increased the utility of the information provided on the medical certificate of death by specifying whether the pneumonia was bacterial or viral, the stroke ischaemic or haemorrhagic and the diabetes type 1 or 2.

Given the highly developed status of the six countries, the distribution of deaths on the three broad GBD groups of health conditions as expected showed that communicable and maternal diseases as well as injuries are minor contributors to their disease burden (Table 1). Non-communicable diseases on average accounted for 67.8% of all causes of death. Only Japan showed an unlikely low proportion (58.5%) that points to the impact that garbage codes can have on the cause pattern of mortality.

Since most deaths in these countries occur at older ages, it might be expected that these age groups also account for most of the garbage codes. That is indeed the case; in all six countries, between 85 and 92% of the garbage codes occur at ages 65

years and over. However, garbage codes are not limited to the oldest ages; they also comprise a sizeable proportion of deaths in several other age groups, particularly in the younger adult age groups where they constitute between 20 and 30% of all deaths. Even for child deaths, we do not know the true underlying cause in 10% of cases (Fig. 1). Deaths at these ages are often entirely preventable, but to do so public policy must be guided by accurate and specific COD data and how they are changing.

The first ANACONDA typology classifies the total amount of garbage codes according to five categories of certification errors and shows the percentage of each in relation to total deaths, and as a percentage of the total number of garbage codes (Table 2). In all countries except Germany, insufficiently specified COD (Category 5) was the most common error. The reporting of intermediary instead of underlying COD (Category 3) was the second most frequent issue in Australia, Canada, Japan and Switzerland. In Denmark, the second most frequent reporting flaw was Category 1 (the reporting of signs, symptoms or other ill-defined COD), followed by the reporting of an intermediary COD (Category 3). It is to be expected that all countries assign some deaths to ICD-10 code R99 (Other ill-defined and unspecified causes of mortality) since there always will be deaths for which the cause was unknown. However, Denmark and Japan stand out by coding more than 7% of all deaths to

category 1, which is much higher than in any of the other countries.

On average, certifiers in the six countries reported an intermediary COD (Category 3) as being the underlying COD for 9% of deaths. This error was particularly common in Japan (13%) and Germany (11%), almost twice as high as in the other countries. Further investigation showed that “Heart failure, unspecified” (I50.9) and “Congestive heart failure” (I50.0) were used more frequently in Japan and Germany than in other countries. Regarding the two remaining categories, irrespective of country, very few doctors certified an impossible COD (Category 2) or just provided the immediate COD (Category 4). The second typology of garbage codes provides important insight into the potential impact that garbage codes might have in guiding or misguiding public policy. This categorization showed a similar pattern for all countries with the “very high” impact category being the biggest problem for all six countries, followed by the “low” impact category, except for Australia, where the order of these top two impact categories was inverted in comparison with all other countries (Table 3). However, of note, the percentage at the “very high” impact level showed substantial differences between countries. For instance, in Japan, 21% of all deaths and 58% of all garbage codes had a very high impact for policy, while in Australia the comparable figures were only 8% and 35%, respectively. A closer investigation of the specific codes revealed that

the three ICD codes that account for most of the “very high” impact garbage codes were “Other ill-defined and unspecified deaths” (R99), “Heart failure” (I50.9) and “Senility” (R54).

The high and medium levels typically only accounted each for 2–4% of all deaths in all countries. The most common misdiagnosis for the high level was Essential (primary) hypertension (I10), Unspecified external factor (X59) and Gastrointestinal bleeding (K92.2), while for the medium level it was Unspecified cancer (C80.9) for all. The low-impact garbage codes were generally between 6% (Switzerland) and 11% (Japan) of all deaths and, on average, were used for 8% of all deaths, accounting for 31% of all garbage codes. In the low-impact group, the biggest contributor was “Stroke not specified” (I64), except for Japan where certifiers seem to better distinguish between haemorrhagic or infarction stroke, but not between the different types of pneumonia).

Standardizing the age structure for each country had a minor impact on the proportions of garbage codes for five of the countries. Only in Japan, where a higher proportion of deaths occur at the very oldest ages, age standardization reduced the amount of total garbage codes by 6%. However, Japan still remained the country with the highest proportion of deaths assigned to garbage codes (Table 3). The unusable codes among the leading causes of death are identified by red cells in Table 4. All

countries, except Australia, had at least one cell with unusable codes (red) among the top 10 causes of male deaths and all had one or more among the top 20 causes (Table 4). Japan had four red cells, and three of these were among the top 10 causes. Denmark and Canada had one red cell, while Switzerland and Germany had two red cells in the top half of the ranking. The specific unusable causes were very similar across the countries and included Other ill-defined and unspecified deaths (R99), Unspecified heart failure (I50.9), Congestive heart failure (I50.0), Unspecified cardiac arrest (I46.9), Unspecified malignant neoplasm (C80.9), Senility (R54), Pneumonitis (J69) and Unattended deaths (R98). With the exception of Japan, all countries also had two cells with insufficiently specified causes (orange) among the 20 leading causes of death.

For females, the 20 top disease rankings were even more saturated with unusable and poorly specified disease groups and included, apart from those mentioned for males, Essential (primary) hypertension (I10), Septicaemia (A41.9) and Malignant neoplasm of overlapping lesion of bronchus and lung (C34.8). Japan and Switzerland each had five red cells among the leading causes of female deaths, Denmark four, Canada and Germany three and Australia two.

Fortunately, a relatively small number of ICD codes are responsible for the major share of the garbage codes in these countries. In Table 5, the most common garbage codes for each country

have been identified. If these relatively few codes were not used, it would lead to a 25% reduction in the total amount of garbage codes. In Japan, this could be achieved very easily by avoiding the use of two codes: Senility (R54) and Unspecified heart failure (I50.9). As shown in Table 5, Denmark, Germany and Switzerland would need to focus on three codes and Canada and Australia, respectively, on six and seven. In other words, significant reductions in garbage codes could be achieved if certifiers, instead of just certifying that patients died from old age, heart failure, hypertension, septicaemia and unspecified cancer, could more accurately report the sequence of events leading to death, including the underlying cause of that sequence. As noted above, the problem with the code R99 (ill-defined and unspecified causes of mortality) is not that it cannot be used but that it is over-used, e.g. it is unlikely that no cause could be identified in Denmark for 5% of all deaths.

#### D. 結論

Although the countries included in the study have highly developed mortality information systems and have been producing COD data aligned with international standards for many years, the assessment of their data still revealed that there were some unexpected deficiencies in their statistics that could have significant implications for policy dialogue, monitoring health progress and evaluating intervention impact. This would appear to be due, in large part, to the lack of standardized instructions for medical certifiers

about how to correctly complete the death certificate. All six countries declared that such basic information is not part of the standard training provided to young doctors. While physicians may not need to be trained to use the ICD, they should at least be taught how to properly certify the sequence of events leading to death to ensure that coders can identify correctly the underlying cause that led to the person's death. It is this information that is critical for guiding public health policies to further reduce premature mortality and address the rising costs of health care.

In systems where all deaths are registered with a cause, the bias in the data is largely determined by the level and type of garbage codes they contain. To certify that 17% of all deaths in the 70-plus age group were due to old age (Japan) is unhelpful if health authorities want to have a better understanding of disease management in later life. Most people in the considered countries die at older ages and are likely to have had frequent contact with the health system. It is reasonable therefore to assume that comprehensive medical records exist that should allow physicians to more accurately certify deaths. The tendency to assign "old age" as a COD strongly suggests that the certifier has not been trained and is unaware of the important public health use of the death certificate.

While all countries will have a small proportion of deaths where the circumstances leading to death are either

not known or cannot be further specified, hence justifying the use of the R99 code “Other ill-defined and unspecified deaths”, it is of concern when this cause appears among the leading causes. The same can be said for “Unspecified heart failure”, which is an intermediary COD and which accounts for between 3 and 14% of the garbage codes in the six countries examined. Rather, physicians should specify the underlying cause that led to death, which in the case of heart failure could, among others, be myocardial infarction, chronic renal failure, cerebrovascular accident, poisoning and haemorrhage.

Decreasing the proportion of deaths that are of no or little policy value should be a priority for all country health information systems. This assessment and analysis have shown that it is possible for health authorities to quickly obtain insight into the quality problems and certification errors in the data, which can assist them to take corrective action. The results of the analysis reveal the main certification errors committed by doctors and identify the CODs that introduce bias into the leading causes of death. As demonstrated, the quantity, severity and type of garbage codes appearing in the national cause of death data vary across countries, suggesting that certification problems and coding may be somewhat culture specific. Identifying the specific garbage codes that produce the most unusable data in each country is an essential first step so that strategies can be tailored and developed to determine effective ways to train or inform certifiers. This

will help certifiers to be more specific when they complete medical death certificates and to avoid committing errors that lead to garbage codes. Being aware of quality problems in the data can also assist the authorities responsible for publishing the COD data to provide the explanations needed to correctly interpret the statistics. For instance, in Australia the government agency that publishes the COD data is careful to add the poisoning agent when it publishes data on the accidental poisoning garbage codes such as X42 and X44, thus increasing the information content of the data for policy that normally would be missing from these garbage codes.

National COD data represent a compilation of data from different geographic areas and health facilities, which may vary in their death certification practices, and hence accuracy. It is therefore advisable that countries undertake subnational assessments to verify how certification practices vary and tailor intervention strategies accordingly with more local approaches. For instance, lack of certain diagnostic imaging and analysis and under-staffing can lead to less-than-optimal medical records and make it even more challenging to correctly certify the COD.

Undertaking this type of assessment and communicating the findings to health authorities and medical associations will result in greater



awareness of the need to pay more attention to the quality of medical certification. Medical schools in all six countries should give higher priority to the certification duty of their profession, and correct medical certification certainly should be included as a compulsory element of the induction programs for interns. Doctors perform a very important public health function in documenting the COD of their patients, not only for the families of the deceased, but also for society. They are generally unaware of this, or of its importance for public policy. Without reliable and detailed information on the leading CODs, and how they are changing, health planning and policy will be less cost-effective than otherwise might be the case, potentially resulting in lost opportunities to improve population health.

While ANACONDA cannot verify whether the physician diagnosed the correct COD or whether a COD was miscoded, it can detect whether the code assigned is a valid underlying cause and whether the certifier originally completed the death certificate according to ICD guidance. Adopting the ICD classification without adhering to its rules and standards for coding and guidance for certification will not provide good-quality COD information for public health use. This study has demonstrated that even for countries with very advanced health information systems, it is very informative to undertake an assessment of the COD data as the information content may be reduced by a high proportion of unusable and insufficiently specified causes.

Once the data have been evaluated and the specific problems revealed, focused action should be taken to reduce the amount of garbage codes by, for example, introducing certification training for hospital interns and awareness raising in the medical community of the important functions of the death certificate for the national health information system. The large and complex bureaucracy that all countries have established to collect these data needs to meet the demands of increasingly sophisticated and complex health systems and provide them with the detailed information required for avoiding premature deaths and keeping people alive and healthy for as long as possible.

\* 本稿は、「Mikkelsen L, Iburg, KM, Adair T, Fürst T, Hegnauer M, von der Lippe E, Moran L, Nomura S, Sakamoto H, Shibuya K, Wengler A, Willbond S, Wood P, Lopez AD. **Assessing the quality of cause of death data in six high-income countries: Australia, Canada, Denmark, Germany, Japan and Switzerland.** Int J Public Health. 2020 Jan; 65, 17–28.」に掲載された。

## E. 研究発表

### 1. 論文発表

Mikkelsen L, Iburg, KM, Adair T, Fürst T, Hegnauer M, von der Lippe E, Moran L, Nomura S, Sakamoto H, Shibuya K, Wengler A, Willbond S, Wood P, Lopez AD. **Assessing the quality of cause of death data in six high-income countries: Australia, Canada, Denmark,**

**Germany, Japan and Switzerland.** Int J Public  
Health. 2020 Jan; 65, 17–28.

2. 学会発表

特になし

F. 知的財産権の出願・登録状況

( 予定を含む。 )

1. 特許取得

特になし

2. 実用新案登録

特になし

3. その他

特になし



厚生労働科学研究費補助金(地球規模保健課題推進研究事業)

「我が国の世界保健総会等における効果的なプレゼンスの確立に関する研究」(H29-地球規模一般-002)

平成30年度分研究報告書

Global Health Diplomacy Workshop

研究担者	明石秀親	国立国際医療研究センター 連携協力部長
	三好明	国立国際医療研究センター 人材開発部長
	坂元晴香	東京大学大学院医学系研究科 国際保健政策学教室 特任研究員
研究協力者	渋谷健司	東京大学大学院医学系研究科 国際保健政策学教室 教授
	野村周平	東京大学大学院医学系研究科 国際保健政策学教室 助教

研究要旨

グローバル・ヘルスの重要性が高まっている中、我が国が主導してグローバルヘルスの課題を前進させ、主要会合において効果的に議論を先導する役割を果たすためには、そのようなことを可能とする人材の育成が急務である。本研究は、同じようにグローバルヘルス領域での人材育成を優先課題として掲げるタイと協力し、日・タイ双方の将来を担う若手人材に対し会議でのスピーチや交渉、効果的・戦略的介入、ファシリテーション等の能力開発を行うものである。

研修は年に2回(日・タイ 各1回)、2～4日間の日程で開催され、参加者たちはグローバルヘルスの概況から具体的な交渉術まで、グローバル・ヘルス領域における基礎的スキルについて包括的学ぶ。研修の最後には参加者全員に対してアンケート調査を実施し今後 WHO 総会等国際会議に参加する際や、日々の業務においてどのような点が有用だったか聞き取りを行い、研修内容の適性や効果を確認する。

## A. 研究目的

グローバル・ヘルスの重要性が高まっている中、我が国が主導してグローバル・ヘルスの課題を前進させ、主要会合において効果的に議論を先導する役割を果たすためには、そのようなことを可能とする人材の育成が急務である。本研究は、同じようにグローバル・ヘルス領域での人材育成を優先課題として掲げるタイと協力し、日・タイ双方の将来を担う若手人材に対し会議でのスピーチや交渉、効果的・戦略的介入、ファシリテーション等の能力開発を行うものである。

## B. 研究方法

年に2回(日本・タイ各1回)で、グローバルヘルス領域の中でも特に保健外交に焦点を当てた研修を開催する。対象は、厚生労働省保健省 アカデミア、NGO職員等グローバルヘルスに関わる若手中堅とする。また、日本とタイ以外にも、グローバルヘルス領域における人材開発に興味を有する国については参加を促す(フィリピン、ラオス等)。

研修は数日間にわたり行い、扱った内容については主に以下の内容とする：

- 1) グローバル・ヘルスの概況
- 2) グローバル・ヘルスにおける主要アクターの変化
- 3) グローバル・ヘルスの主要課題の傾向
- 4) WHO 総会等の WHO governing body における意思決定プロセスのあり方
- 5) WHO 総会等における効果的なインターベションの構築方法
- 6) 国際会議等における交渉術

ワークショップ終了時点で参加者全員を対象としたアンケート調査を実施し、今後WHO総会等国際会議に参加

する際や、日々の業務においてどのような点が有用だったか聞き取りを行い、研修内容の適性や効果を確認する。

## C. 研究結果

平成31年度には5月に2泊3日の日程でタイにて、12月には1泊2日の日程で日本にて研修を開催した(プログラム詳細については参考資料として掲載)。日本の研修は前年に比べ参加対象者を絞り、25名の参加があった他、タイの公衆衛生省と外務省及び中国から国際保健の有識者を招聘し、研修全般に渡り支援を受けた。

日本での研修では、最初にグローバルヘルスの概況、グローバルヘルス領域のアクターの変化、現在のグローバルヘルスにおける主要課題等について講義を行った。その後、WHO総会における主要議題のうち、「がん患者における緩和ケア」並びに「結核の撲滅に向けて」の2つについて、参加者各自に発言を作成してもらい、実際に発言・プレゼンテーションを実施した。交渉術に関しては、「WHOへの分担金増加について」を取り上げ、参加者各自をスタンスの異なる複数の国に割り振り、実際の交渉の練習をおこなった。

研修後のアンケート調査では、大半の参加者から参考になったという好意的なフィードバックが得られた。WHO総会等の国際会議に参加できる機会是非常に限られているが、実際に発言をする可能性のある参加者に絞ったことも研修が効果的であったとされる。また、関連会合への参加が直近で予定されていない参加者にとっても、日本、タ

イ、中国の3カ国による関連会合への準備プロセスに関する情報や交渉の練習については、日常の業務においても参考となる内容であったとの回答があった。

#### D. 結論

我が国がグローバルヘルスを牽引していく上で、グローバルヘルス領域で活躍できる人材の育成は急務であるが、今までは体系的なトレーニングの機会は限られていた。今回実施した研修は包括的にグローバルヘルス領域の全体像を学べるとともに、発言や交渉等に実践も含まれており、参加者にとって非常に満足度の高いものとなった。他、日本及びタイ双方における人的ネットワークの構築にも貢献した。

今後とも継続して人材育成研修を実施していくことが望ましい。

#### E. 研究発表

##### 1. 論文発表

特になし

##### 2. 学会発表

特になし

#### F. 知的財産権の出願・登録状況

( 予定を含む。 )

##### 1. 特許取得

特になし

##### 2. 実用新案登録

特になし

##### 3. その他

特になし



# Global Health Diplomacy Workshop

30 November – 1 December, 2019

Toshi Center Hotel Room 701, Tokyo, Japan

Department of Global Health Policy, University of Tokyo, Tokyo, Japan

Institute for Global Health Policy Research, Bureau of International Health Cooperation, National Center for Global Health and Medicine, Tokyo, Japan

Human Resource Strategy Center for Global Health, National Center for Global Health and Medicine, Tokyo, Japan

## 1) Objectives

Global health, defined as issues that directly or indirectly affect health that can transcend national boundaries, needs a pooling of experience and knowledge and a two-way flow between developed and developing countries. Global health is a global political engagement at the intersection of health, diplomacy and global collective action.

World Health Assembly (WHA) has been still main arena for advancing global health, while global health agenda is often discussed outside of health sector such as G7/G20 summit, Tokyo International Conference on African Development (TICAD) and the United Nation High level meeting. More political attention has been paid to health issues than ever and those who are working at global health area is required not only technical knowledge and skills on global health, but also required practical diplomacy skills such as negotiation and communication with diverse stakeholders.

This workshop aims to:

1. Develop and strengthen the capacity of the next generation of leaders in global health diplomacy with a special focus on the changing landscape and context in global health and practical applications to health diplomacy at major meetings such as the WHA, G7/ G20 and the United Nation High Level meeting
2. Strengthen a network and partnership in collaboration with key stakeholders both within and outside Japan; and
3. Build capacity to prepare effectively for decision-making meetings such as WHA and board meeting of international organizations.



## 2) Target participants

1. Young and middle career professionals who will attend upcoming or future WHA or any other board meeting of international organizations. They are expected to be well prepared for the board meetings of WHO and other international organizations, as well as to be actively participate into the meetings through its preparatory process.
2. Young and middle career professionals who are in charge of global health policy at each organization. They are expected to well translate global health policy into their respective activities at regional, national and community level.

## 3) Resource persons

Prof. Kenji Shibuya, Visiting Professor and Chair, Department of Global Health Policy (GHP), Graduate School of Medicine, The University of Tokyo  
Professor and Director, University Institute for Population Health, King's College London

Prof. Hiroki Nakatani, Professor to Global Initiatives, Keio University, Japan  
Director, Human Resource Strategy Center for Global Health, National Center for Global Health and Medicine (NCGM)  
Board Chair, Global Health Innovation Technology Fund (GHIT)

Dr. Hajime Inoue, Director General, Bureau of Strategic Planning, National Center for Global Health and Medicine (NCGM)  
Director, Institute for Global Health Policy Research (iGHP), National Center for Global Health and Medicine (NCGM)

Dr. Suwit Wibulpolprasert, Vice Chair, International Health Policy Program Foundation, Health Intervention and Technology Assessment Foundation, Thailand

Dr. Warisa Panichkriangkrai, International Health Policy Program, Ministry of Public Health, Thailand

Mr. Charlie Garnjana-Goonchorn, Ministry of Foreign Affairs, Thailand

Dr. Kun Tang, Research Center for Public Health, Tsinghua University School of Medicine

Dr. Yosuke Kita, Ministry of Health, Labour and Welfare (MHLW), Japan

Dr. Hiroshi Matsumura, Ministry of Health, Labour and Welfare (MHLW), Japan

Dr. Kenichi Komada, National Center for Global Health and Medicine

Dr. Masataro Norizuki, National Center for Global Health and Medicine

Ms. Emiko Nishimura, Japan International Cooperation Agency

#### **4) Course organizer**

Department of Global Health Policy (GHP), Graduate School of Medicine, the University of Tokyo

#### **5) Collaborative Institutions/organizations**

Human Resource Strategy Center for Global Health, National Center for Global Health and Medicine (NCGM)

Institute for Global Health Policy Research (iGHP), National Center for Global Health and Medicine (NCGM)

\*This workshop is supported by the Ministry of Health, Labour and Welfare of Japan

## 4) Tentative Agenda

Time (min)	Topic	Description	Speakers/Responsible persons
<b>Day 1 (Saturday, 30 November) [MC : ]</b>			
9:00 – 9:20 (20)	<u>Session 1</u> Self-introduction	<ul style="list-style-type: none"> <li>• Ice breaking session</li> <li>• Self-Introduction</li> </ul>	Anna Kubota
9:20 – 9:40 (20)	<u>Session 2</u> Course overview	<ul style="list-style-type: none"> <li>• Overview of the course: background, objectives, expected outcomes, activities</li> <li>• Sharing objectives: Why do we need a capacity-building mechanism for global health diplomacy?</li> </ul>	Aya Ishizuka
9:40 – 10:40 (60)	<u>Session 3</u> Landscape and evolution of global health	<ul style="list-style-type: none"> <li>• Global Health Landscape               <ul style="list-style-type: none"> <li>- Definition, evolution of “global health architecture”</li> <li>- Who is who in GH? (GO/development agencies: e.g, JICA/ International organizations/ private sector/ foundations/ academia)</li> </ul> </li> <li>• Changing landscape: the role and contribution of global health diplomacy in global health policy development</li> </ul>	MHLW
10:40 – 11:00 (20)		Coffee Break	
11:00 – 12:15 (75)	<u>Session 4</u> Global Diplomacy Health	<ul style="list-style-type: none"> <li>• What is Global Health Diplomacy? 20min presentation, 5min Q&amp;A each               <ul style="list-style-type: none"> <li>- Role of Japan in global health (G7, G20)</li> <li>- Role of Thailand in global health</li> <li>- Role of China in global health</li> </ul> </li> </ul>	Japan (MHLW) Thailand China Moderator – Anna Kubota

Time (min)	Topic	Description	Speakers/Responsible persons
12:15– 13:15 (60)		Lunch <ul style="list-style-type: none"> <li>Lunch is provided by UTokyo</li> </ul>	
13:15 – 13:45 (30)	<u>Session 5</u> Intervention #1 (preparation)	Assignment #1: Individual intervention First swimming to draft an intervention on: <ul style="list-style-type: none"> <li>Cancer prevention and control in the context of an integrated approach (WHA70.31)</li> </ul>	all resource person  Moderator – Aya Ishizuka
13:45-15:15 (90)	<u>Session 6</u> Intervention #1 (Mock-up)	Mocked up assignment #1: making interventions <ul style="list-style-type: none"> <li>Individual intervention (3min*25 person = 75min)</li> </ul> Comments/feedbacks by resource person (15min)	all resource persons  Main moderator – Aya Ishizuka
13:45-15:15 (15)		Coffee Break	
15:30-16:45 (75)	<u>Session 7</u> Forming national position	Forming national position <ul style="list-style-type: none"> <li>Presentation (20min * 3 countries)</li> <li>Q&amp;A session (5 min* 3 countries)</li> </ul>	Thailand China Japan (MHLW)  Moderator – Anna Kubota
16:45 – 17:00 (15)	<u>Session 8</u> Closure of the day	<ul style="list-style-type: none"> <li>Wrap up, Q&amp;A</li> </ul>	all resource persons  Moderator – Anna Kubota

## Day 2 (Sunday, 1 December) [MC:]

9:00 – 9:10 (10)	<u>Session 9</u> Debriefing	Debriefing by lucky participant	Anna Kubota
9:10—9:55 (45)	<u>Session 10</u> Negotiation	Negotiation in Global Health: the Principles	Dr. Charlie
9:55– 11:25 (90)	<u>Session 11</u> Negotiation practice	Negotiation in Global Health the Real practice [+healthy break] <ul style="list-style-type: none"> <li>• Brief overview of the agenda</li> <li>• Group work (6 groups) [50 mins]               <ul style="list-style-type: none"> <li>- Each group will have 5 – 6 participants and each participant will be assigned as a member state with clear position and country- specific context</li> <li>- Each group will negotiate for their position</li> </ul> </li> <li>• Summary of the negotiation and lessons learned from each group [3 min per group, 20 mins]</li> <li>• Conclusion &amp; wrap up by Dr. Charlie [10min]</li> </ul>	Dr. Charlie and all resource persons
11:25 – 12:10 (45)	<u>Session 12</u> WHA highlights	Panel discussion <ul style="list-style-type: none"> <li>• Dr. Suwit and Dr. Nakatani share experiences on WHA</li> <li>• Q&amp;A</li> </ul>	Panellists: Dr. Suwit, Dr. Nakatani  Moderator – Aya Ishizuka
12:10 – 13:10 (60)		Photo session  Lunch	
13:10 – 13:40 (20)	<u>Session 13</u> Drafting intervention	<ul style="list-style-type: none"> <li>• What is an intervention?</li> <li>• Interventions: DO and DON'T</li> </ul>	Dr. Nakatani  Haruka Sakamoto

	(presentation)	<ul style="list-style-type: none"> <li>• How to make a good intervention?</li> </ul>	
13:40– 14:50 (70)	<u>Session 14</u> Intervention #2 (preparation)	<p>Assignment #2 Individual intervention Second swimming to study documents and prepare interventions on:</p> <ul style="list-style-type: none"> <li>• Ending tuberculosis: Draft global strategy for tuberculosis research and innovation (EB146/11)</li> </ul>	<p>all resource persons Moderator – Aya Ishizuka</p>
14:50 – 15:10 (20)		Coffee break	
15:10 – 16:20 (70)	<u>Session 15</u> Intervention #2 (Mock-up)	<p>Mocked up for assignment #2: making interventions</p> <ul style="list-style-type: none"> <li>• Making interventions</li> <li>• Feedback for intervention</li> <li>• Wrap up</li> </ul>	<p>all resource persons moderator – Aya Ishizuka</p>
16:20 – 17:00 (40)	<u>Session 16</u> Course summary	<ul style="list-style-type: none"> <li>▪ Ground final comment</li> <li>▪ Summary of the course</li> <li>▪ Feedback from participants</li> </ul>	<p>Prof. Shibuya (UTokyo) all resource persons moderator – Anna Kubota</p>



# Assessing the quality of cause of death data in six high-income countries: Australia, Canada, Denmark, Germany, Japan and Switzerland

Lene Mikkelsen<sup>1</sup> · Kim Moesgaard Iburg<sup>2</sup> · Tim Adair<sup>1</sup> · Thomas Fürst<sup>3</sup> · Michael Hegnauer<sup>3</sup> · Elena von der Lippe<sup>4</sup> · Lauren Moran<sup>5</sup> · Shuhei Nomura<sup>6</sup> · Haruka Sakamoto<sup>6</sup> · Kenji Shibuya<sup>7</sup> · Annelene Wengler<sup>4</sup> · Stephanie Willbond<sup>8</sup> · Patricia Wood<sup>8</sup> · Alan D. Lopez<sup>1</sup> 

Received: 15 October 2019 / Revised: 19 December 2019 / Accepted: 23 December 2019 / Published online: 14 January 2020  
© Swiss School of Public Health (SSPH+) 2020

## Abstract

**Objectives** To assess the policy utility of national cause of death (COD) data of six high-income countries with highly developed health information systems.

**Methods** National COD data sets from Australia, Canada, Denmark, Germany, Japan and Switzerland for 2015 or 2016 were assessed by applying the ANACONDA software tool. Levels, patterns and distributions of unusable and insufficiently specified “garbage” codes were analysed.

**Results** The average proportion of unusable COD was 18% across the six countries, ranging from 14% in Australia and Canada to 25% in Japan. Insufficiently specified codes accounted for a further 8% of deaths, on average, varying from 6% in Switzerland to 11% in Japan. The most commonly used garbage codes were Other ill-defined and unspecified deaths (R99), Heart failure (I50.9) and Senility (R54).

**Conclusions** COD certification errors are common, even in countries with very advanced health information systems, greatly reducing the policy value of mortality data. All countries should routinely provide certification training for hospital interns and raise awareness among doctors of their public health responsibility to certify deaths correctly and usefully for public health policy.

**Keywords** Causes of death · Medical certification · Data quality · Garbage codes · Assessment of data

## Introduction

The Global Burden of Disease (GBD) studies have documented remarkable improvements in health that have occurred during the last decade, but also how unevenly health outcomes are distributed between and within populations. A recent study has raised concerns that adult death rates for many diseases have plateaued and, in some cases, increased, including in high-income countries (Roth et al. 2018). Subnational data have demonstrated surprising health inequality in some countries with well-developed health systems (AIHW 2018; Chammartin et al. 2016;

Mahapatra et al. 2007; Roth and Dwyer-Lindgren 2017). To be able to monitor such health trends and the impact of interventions accurately, valid, reliable, regular and up-to-date national mortality and morbidity data are essential (Lopez 2013; Shibuya 2006).

The global health goals and accountability for their achievements have led to significant interest in monitoring data quality and to the development of summary indicators such as the Vital Statistics Performance Index (VSPI) which measures the quality and timeliness of available mortality data (Mikkelsen et al. 2015; Philips et al. 2014). However, to be able to determine what actions need to be taken to improve statistical outputs, a more comprehensive review of the data is needed to better understand the main data quality issues and their origins. The usual research methodology to assess the accuracy of causes of death (COD) is to undertake an independent review of a sample of medical records and compare the records with the

---

**Electronic supplementary material** The online version of this article (<https://doi.org/10.1007/s00038-019-01325-x>) contains supplementary material, which is available to authorized users.

---

Extended author information available on the last page of the article

cause(s) written on the death certificate (Alpérovitch et al. 2009), or to compare the clinical COD to an autopsy-based COD (Schdev 2001). Such studies, however, are complex and expensive to carry out and usually conducted in only one or a handful of hospitals. The findings have often indicated that even in countries with well-functioning civil registration and vital statistics (CRVS) systems, the quality of the medical certification is not as good as might be expected (Rampatige et al. 2014; Adair et al. 2019). Accuracy in COD certification is likely to be a growing issue in countries experiencing significant population ageing, in particular related to dementia and multiple chronic conditions that make accurate and consistent certification more challenging (Naghavi et al. 2010).

Within this context, it is crucial to be able to understand how well national mortality data systems of high-income countries are performing, given the expectations for them. To address this issue, we assessed the certification specificity and policy utility of the national COD data from six high-income countries with highly developed health information systems: Australia, Canada, Denmark, Germany, Japan and Switzerland.

## Methods

Medical certification of death is a requirement in all the countries included in this study. Certifiers, mostly physicians and special health care providers, are asked to complete a medical death certificate indicating what was, in their opinion, the sequence of morbid events leading to death. Subsequently, the information provided on the death certificate is coded by trained coders, applying the International Statistical Classification of Diseases and Related Health Problems (ICD) and its rules for COD coding, and compiled by health or statistical authorities (WHO 2016).

National data on population and COD coded to ICD-10, by age group and sex, were provided by Australia, Canada and Germany for 2016 and downloaded from the World Health Organization (WHO) website for Denmark, Japan and Switzerland for 2015 (WHO 2019). To evaluate the data sets, the ANACONDA tool (see Annex 1, Mikkelsen et al. 2020) that assesses the quality of national and sub-national COD data was used.

The accuracy of the COD output is dependent on physicians providing enough information on the death certificate for coders to select and code the underlying COD. When this process is not completed correctly, the COD output may contain codes labelled “garbage” codes (Murray and Lopez 1996) because they are of little or no use for policy decision-making. Historically, “garbage” codes are defined as causes that cannot or should not be an underlying cause of death (Naghavi et al. 2010). The term,

despite its inelegance, has now been an integral part of the literature for more than a quarter of a century. Since ANACONDA uses the same concept and definition for these codes, we have retained the original terminology in the paper.

To provide additional insight into the provenance and policy implications of these codes, ANACONDA classifies garbage codes into two distinct typologies. In the first typology, garbage codes are grouped into five categories based on ICD concepts:

- Category 1: Codes relating to symptoms, signs and ill-defined conditions (most drawn from ICD Chapter XVIII); e.g. R99 Other ill-defined and unspecified causes of mortality).
- Category 2: Codes that are not valid as an underlying cause of death (e.g. T12 Fracture of lower limb).
- Category 3: Codes that represent intermediate causes of death (e.g. I50 Heart failure).
- Category 4: Codes that represent immediate causes of death (e.g. I46 Cardiac arrest).
- Category 5: Codes that represent insufficiently specified causes within ICD chapters or within a larger disease category (e.g. D48.9 Neoplasm of uncertain or unknown behaviour, unspecified).

ANACONDA also includes a second typology, which focuses much more on the potential impact that garbage codes might have on misleading policy and planning (Naghavi 2020). In this typology, garbage codes are grouped into four impact levels, from “very high” (level 1) to “low” (level 4):

- Very high (level 1): This highest level represents causes for which the true underlying cause could be a communicable or non-communicable disease, or the result of an injury (e.g. septicaemia).
- High (level 2): These are causes with substantial negative impact, but where the true cause is mostly limited to one of the three broad cause groups mentioned above, e.g. essential (primary) hypertension that can be due to different non-communicable diseases.
- Medium (level 3): CODs classified to the third level are only considered to have a medium negative impact for policy since, in this case, the underlying cause is likely to be within the same ICD chapter (e.g. unspecified cancer).
- Low (level 4): Causes classified as having low negative impact are those where the true underlying cause is likely to be confined to a single disease or injury group, such as unspecified stroke or unspecified pneumonia.

These “impact-level” categories can be further grouped into those that provide no or little useful information about the true underlying cause (levels 1–3), which we therefore



refer to as “unusable”, and those in level 4 that provide sufficient information to guide public health interventions but not for research and technology development (Naghavi et al. 2010). We refer to the latter as “insufficiently specified” causes as they impair evidence-based health policy processes only to a limited extent. However, correcting these becomes increasingly important if our health information systems are to appropriately guide research, hospital financial flows, resource allocation and healthcare strategies (WHO 2019). This is likely to be particularly of relevance in countries with ageing populations where most deaths happen in hospitals, primarily from non-communicable diseases.

In countries where unusable codes are assigned to a large proportion of all deaths, the true COD distribution can be seriously distorted and thereby mislead policy dialogue. This is particularly serious when garbage codes are common among the leading causes of death. From the input data, ANACONDA automatically provides a listing of the top-20 COD for males and females and indicates those that are considered to be unusable (levels 1–3) or insufficiently specified (level 4). The higher the number of these codes and the higher their ranking, the greater their impact on misinforming policy is going to be.

The relationship between age and garbage codes is also investigated with the ANACONDA tool to verify whether they are particular to certain age groups. Furthermore, given that some differences might exist in population age structure between the six countries, we used the global proportion of deaths by age from the latest Global Burden of Disease Study as the standard (Murray et al. 2018) to age-standardize the garbage codes in the countries.

Data completeness, a key indicator of data quality, was not considered, given that all six countries have civil registration systems that register all deaths. The focus of our data quality analysis therefore was limited to the levels, patterns and distribution of garbage codes.

## Results

Despite the six countries being from three different geographic regions—Europe, Asia-Pacific and North America—their health systems and socio-economic indicators are comparable (Annex 2 Table 1S). Life expectancy varies from 78 to 81 years for males and 83 to 87 years for females, with all having very low child mortality rates of 2–5 per 1000 live born. The total fertility rates and proportion of 65 years and above indicate that Australia and Canada have somewhat younger populations than Denmark, Germany, Japan and Switzerland. Switzerland, with a private health insurance system, spends significantly more money on health care per person than the other

countries. The Socio-Demographic Index (SDI) (Wang et al. 2016), a measure of national development based on income, education and fertility, is high for all countries, especially Denmark, while Germany and Denmark are doing slightly less well than the others on the Health Access and Quality Index (HAQ). The VSPI(Q), a measure of the overall quality of mortality data calculated by ANACONDA, is the highest in Australia and the lowest in Japan.

In the six countries studied, the average proportion of unusable codes (levels 1–3) was 18%, being slightly lower (14%) in Australia and Canada, while higher in Japan, where one in four deaths is assigned an unusable cause (Table 1). Insufficiently specified codes (level 4), in addition, averaged 8%, varying from 6% in Switzerland to 11% in Japan. Three of the most common CODs in the insufficiently specified group are pneumonia, stroke and diabetes all unspecified. For these CODs, the certifier could have increased the utility of the information provided on the medical certificate of death by specifying whether the pneumonia was bacterial or viral, the stroke ischaemic or haemorrhagic and the diabetes type 1 or 2.

Given the highly developed status of the six countries, the distribution of deaths on the three broad GBD groups of health conditions as expected showed that communicable and maternal diseases as well as injuries are minor contributors to their disease burden (Table 1). Non-communicable diseases on average accounted for 67.8% of all causes of death. Only Japan showed an unlikely low proportion (58.5%) that points to the impact that garbage codes can have on the cause pattern of mortality.

Since most deaths in these countries occur at older ages, it might be expected that these age groups also account for most of the garbage codes. That is indeed the case; in all six countries, between 85 and 92% of the garbage codes occur at ages 65 years and over. However, garbage codes are not limited to the oldest ages; they also comprise a sizeable proportion of deaths in several other age groups, particularly in the younger adult age groups where they constitute between 20 and 30% of all deaths. Even for child deaths, we do not know the true underlying cause in 10% of cases (Fig. 1). Deaths at these ages are often entirely preventable, but to do so public policy must be guided by accurate and specific COD data and how they are changing.

The first ANACONDA typology classifies the total amount of garbage codes according to five categories of certification errors and shows the percentage of each in relation to total deaths, and as a percentage of the total number of garbage codes (Table 2). In all countries except Germany, insufficiently specified COD (Category 5) was the most common error. The reporting of intermediary instead of underlying COD (Category 3) was the second most frequent issue in Australia, Canada, Japan and

**Table 1** Total number of deaths and percentage of death by three Global Burden of Disease broad cause groups<sup>a</sup> and unusable and insufficiently specified causes, Australia, Canada, Denmark, Germany, Japan and Switzerland, 2015–2016

Country	Total number of deaths	Group 1% communicable	Group 2% NCDs	Group 3% external causes	% Unusable causes	% Insufficiently specified causes	Total
Australia	158.504	1.3	71.1	5.0	14.1	8.2	100
Canada	267.213	1.4	72.1	4.5	14.3	7.6	100
Denmark	52.224	1.9	66.9	2.9	20.0	8.1	100
Germany	910.902	1.1	69.6	3.6	18.7	7.0	100
Japan	1290.444	1.2	58.5	4.5	25.0	10.7	100
Switzerland	67.606	1.6	68.7	5.1	18.3	6.2	100
Mean		1.4	67.8	4.3	18.4	8.0	100

<sup>a</sup>Group I: Infections and parasitic diseases (e.g. TB, pneumonia, diarrhoea, malaria, measles); maternal/perinatal causes (e.g. maternal haemorrhage, birth trauma); malnutrition

Group II: Non-communicable diseases (e.g. cancer, diabetes, heart disease, stroke); mental health conditions (e.g. schizophrenia)

Group III: Injuries (e.g. accidents, homicide, suicide) often referred to as “external diseases” or “non-natural” cause of death

Switzerland. In Denmark, the second most frequent reporting flaw was Category 1 (the reporting of signs, symptoms or other ill-defined COD), followed by the reporting of an intermediary COD (Category 3). It is to be expected that all countries assign some deaths to ICD-10 code R99 (Other ill-defined and unspecified causes of mortality) since there always will be deaths for which the cause was unknown. However, Denmark and Japan stand out by coding more than 7% of all deaths to category 1, which is much higher than in any of the other countries. Further in-depth analysis revealed the reason in Japan being because of using Senility (R54) as a COD, while in Denmark, it is indeed the frequent use of the code R99.

On average, certifiers in the six countries reported an intermediary COD (Category 3) as being the underlying COD for 9% of deaths. This error was particularly common in Japan (13%) and Germany (11%), almost twice as high as in the other countries. Further investigation showed that “Heart failure, unspecified” (I50.9) and “Congestive heart failure” (I50.0) were used more frequently in Japan and Germany than in other countries. Regarding the two remaining categories, irrespective of country, very few doctors certified an impossible COD (Category 2) or just provided the immediate COD (Category 4).

The second typology of garbage codes provides important insight into the potential impact that garbage codes might have in guiding or misguiding public policy. This categorization showed a similar pattern for all countries with the “very high” impact category being the biggest problem for all six countries, followed by the “low” impact category, except for Australia, where the order of these top two impact categories was inverted in comparison with all other countries (Table 3). However, of note, the percentage at the “very high” impact level showed substantial


differences between countries. For instance, in Japan, 21% of all deaths and 58% of all garbage codes had a very high impact for policy, while in Australia the comparable figures were only 8% and 35%, respectively. A closer investigation of the specific codes revealed that the three ICD codes that account for most of the “very high” impact garbage codes were “Other ill-defined and unspecified deaths” (R99), “Heart failure” (I50.9) and “Senility” (R54).

The high and medium levels typically only accounted each for 2–4% of all deaths in all countries. The most common misdiagnosis for the high level was Essential (primary) hypertension (I10), Unspecified external factor (X59) and Gastrointestinal bleeding (K92.2), while for the medium level it was Unspecified cancer (C80.9) for all. The low-impact garbage codes were generally between 6% (Switzerland) and 11% (Japan) of all deaths and, on average, were used for 8% of all deaths, accounting for 31% of all garbage codes. In the low-impact group, the biggest contributor was “Stroke not specified” (I64), except for Japan where certifiers seem to better distinguish between haemorrhagic or infarction stroke, but not between the different types of pneumonia).


Standardizing the age structure for each country had a minor impact on the proportions of garbage codes for five of the countries. Only in Japan, where a higher proportion of deaths occur at the very oldest ages, age standardization reduced the amount of total garbage codes by 6%. However, Japan still remained the country with the highest proportion of deaths assigned to garbage codes (Table 3).

The unusable codes among the leading causes of death are identified by red cells in Table 4. All countries, except Australia, had at least one cell with unusable codes (red) among the top 10 causes of male deaths and all had one or


Australia 2016



Canada 2016



Denmark 2015



Germany 2016





Fig. 1 Age distribution of deaths on broad Global Burden of Disease groups and garbage causes for six countries: Australia, Canada, Denmark, Germany, Japan and Switzerland, 2015–2016

Japan 2015



Switzerland 2015




Fig. 1 continued

**Table 2** Number of deaths with a garbage code and % of different garbage types as (i) % of all deaths and (ii) % of deaths with a garbage code (in brackets), Australia, Canada, Denmark, Germany, Japan and Switzerland, 2015–2016

Country	Number of deaths with a garbage code	Category 1 signs, symptoms, ill-defined COD	Category 2 impossible COD	Category 3 intermediate COD	Category 4 immediate COD	Category 5 insufficiently specified COD	Per cent of total garbage codes
Australia 2016	34.829	0.9 (4.3)	1.1 (5.2)	6.6 (30.0)	0.1 (0.7)	13.1 (59.8)	22.0 (100)
Canada 2016	58.503	1.8 (8.2)	1.2 (5.4)	6.6 (30.2)	0.2 (0.9)	12.1 (55.3)	21.9 (100)
Denmark 2015	14.672	7.6 (27.2)	1.3 (4.7)	6.3 (22.4)	0.3 (1.2)	12.5 (44.5)	28.1 (100)
Germany 2016	234.254	3.1 (12.0)	1.1 (4.1)	11.2 (43.6)	0.4 (1.6)	10.0 (38.7)	25.7 (100)
Japan 2015	459.913	7.7 (21.7)	1.1 (3.0)	12.9 (36.2)	1.0 (2.7)	13.0 (36.4)	35.6 (100)
Switzerland 2015	16.601	4.2 (16.9)	1.9 (7.6)	7.8 (31.7)	1.3 (5.1)	9.5 (38.8)	24.6 (100)
Mean		4.2 (15.1)	1.3 (5.0)	8.6 (32.4)	0.6 (2.0)	11.7 (45.6)	26.3 (100)

more among the top 20 causes (Table 4). Japan had four red cells, and three of these were among the top 10 causes. Denmark and Canada had one red cell, while Switzerland and Germany had two red cells in the top half of the

ranking. The specific unusable causes were very similar across the countries and included Other ill-defined and unspecified deaths (R99), Unspecified heart failure (I50.9), Congestive heart failure (I50.0), Unspecified cardiac arrest

**Table 3** Number of deaths with garbage codes, classified by severity of impact, provided as (i) % of total deaths and (ii) % of deaths with a garbage code (in brackets), Australia, Canada, Denmark, Germany, Japan and Switzerland, 2015–2016

Country	Number of deaths with a garbage code	Very high	High	Medium	Low	Total % garbage	Age-adjusted total % garbage
Australia 2016	34.829	7.7 (34.9)	2.0 (9.1)	4.3 (19.5)	8.0 (36.4)	22.0 (100)	21.0
Canada 2016	58.503	8.7 (39.6)	2.0 (9.4)	3.5 (16.2)	7.6 (34.9)	21.9 (100)	20.2
Denmark 2015	14.672	13.5 (47.9)	2.9 (10.2)	3.7 (13.2)	8.1 (28.7)	28.1 (100)	26.1
Germany 2016	234.254	12.5 (48.5)	2.9 (11.3)	3.3 (12.9)	7.0 (27.3)	25.7 (100)	23.7
Japan 2015	459.913	20.8 (58.4)	1.8 (5.0)	2.3 (6.6)	10.7 (30.0)	35.6 (100)	29.3
Switzerland 2015	16.601	12.1 (49.3)	2.8 (11.3)	3.5 (14.1)	6.2 (25.4)	24.6 (100)	21.8
Mean		12.6 (46.4)	2.4 (9.4)	3.4 (13.8)	7.9 (30.5)	26.3 (100)	23.7

(I46.9), Unspecified malignant neoplasm (C80.9), Senility (R54), Pneumonitis (J69) and Unattended deaths (R98). With the exception of Japan, all countries also had two cells with insufficiently specified causes (orange) among the 20 leading causes of death.

For females, the 20 top disease rankings were even more saturated with unusable and poorly specified disease groups and included, apart from those mentioned for males, Essential (primary) hypertension (I10), Septicaemia (A41.9) and Malignant neoplasm of overlapping lesion of bronchus and lung (C34.8). Japan and Switzerland each had five red cells among the leading causes of female deaths, Denmark four, Canada and Germany three and Australia two.

Fortunately, a relatively small number of ICD codes are responsible for the major share of the garbage codes in these countries. In Table 5, the most common garbage codes for each country have been identified. If these relatively few codes were not used, it would lead to a 25% reduction in the total amount of garbage codes. In Japan, this could be achieved very easily by avoiding the use of two codes: Senility (R54) and Unspecified heart failure (I50.9). As shown in Table 5, Denmark, Germany and Switzerland would need to focus on three codes and Canada and Australia, respectively, on six and seven. In other words, significant reductions in garbage codes could be achieved if certifiers, instead of just certifying that patients died from old age, heart failure, hypertension, septicaemia and unspecified cancer, could more accurately report the sequence of events leading to death, including the underlying cause of that sequence. As noted above, the problem with the code R99 (ill-defined and unspecified causes of mortality) is not that it cannot be used but that it is over-used, e.g. it is unlikely that no cause could be identified in Denmark for 5% of all deaths.

## Discussion

Although the countries included in the study have highly developed mortality information systems and have been producing COD data aligned with international standards for many years, the assessment of their data still revealed that there were some unexpected deficiencies in their statistics that could have significant implications for policy dialogue, monitoring health progress and evaluating intervention impact. This would appear to be due, in large part, to the lack of standardized instructions for medical certifiers about how to correctly complete the death certificate. All six countries declared that such basic information is not part of the standard training provided to young doctors. While physicians may not need to be trained to use the ICD, they should at least be taught how to properly certify the sequence of events leading to death to ensure that coders can identify correctly the underlying cause that led to the person's death. It is this information that is critical for guiding public health policies to further reduce premature mortality and address the rising costs of health care.

In systems where all deaths are registered with a cause, the bias in the data is largely determined by the level and type of garbage codes they contain. To certify that 17% of all deaths in the 70-plus age group were due to old age (Japan) is unhelpful if health authorities want to have a better understanding of disease management in later life. Most people in the considered countries die at older ages and are likely to have had frequent contact with the health system. It is reasonable therefore to assume that comprehensive medical records exist that should allow physicians to more accurately certify deaths. The tendency to assign "old age" as a COD strongly suggests that the certifier has not been trained and is unaware of the important public health use of the death certificate.

While all countries will have a small proportion of deaths where the circumstances leading to death are either not known or cannot be further specified, hence justifying

**Table 4** Top-20 ICD causes of death ranked for males and females, Australia, Canada, Denmark, Germany, Japan and Switzerland, 2015–2016**MALES**

Rank	Australia	Canada	Denmark	Germany	Japan	Switzerland
1	Bronchus or lung, unspecified	Bronchus or lung, unspecified	Other ill-defined and unspecified causes of mortality	Atherosclerotic heart disease	Pneumonia, unspecified	Chronic ischaemic heart disease, unspecified
2	Acute myocardial infarction, unspecified	Atherosclerotic heart disease	Bronchus or lung, unspecified	Bronchus or lung, unspecified	Bronchus or lung, unspecified	Bronchus or lung, unspecified
3	Chronic ischaemic heart disease, unspecified	Acute myocardial infarction, unspecified	Malignant neoplasm of prostate	Acute myocardial infarction, unspecified	Stomach, unspecified	Malignant neoplasm of prostate
4	Malignant neoplasm of prostate	Unspecified dementia	Stroke, not specified as haemorrhage or infarction	Malignant neoplasm of prostate	Heart failure, unspecified	Unspecified dementia
5	Unspecified dementia	Malignant neoplasm of prostate	Acute myocardial infarction, unspecified	Heart failure, unspecified	Senility	Other ill-defined and unspecified causes of mortality
6	Chronic obstructive pulmonary disease, unspecified	Chronic obstructive pulmonary disease, unspecified	Unspecified dementia	Other ill-defined and unspecified causes of mortality	Acute myocardial infarction, unspecified	Acute myocardial infarction, unspecified
7	Atherosclerotic heart disease	Stroke, not specified as haemorrhage or infarction	Chronic obstructive pulmonary disease, unspecified	Unspecified dementia	Pneumonitis due to food and vomit	Chronic obstructive pulmonary disease, unspecified
8	Stroke, not specified as haemorrhage or infarction	Colon, unspecified	Chronic obstructive pulmonary disease with acute lower respiratory infection	Chronic obstructive pulmonary disease, unspecified	Liver cell carcinoma	Heart failure, unspecified
9	Pancreas, unspecified	Other ill-defined and unspecified causes of mortality	Chronic ischaemic heart disease, unspecified	Pneumonia, unspecified	Sequelae of cerebral infarction	Unspecified fall, unspecified place
10	Intentional self-harm by hanging, strangulation and suffocation, unspecified place	Pancreas, unspecified	Overlapping lesion of bronchus and lung	Pancreas, unspecified	Cerebral infarction, unspecified	Pneumonia, unspecified
11	Alzheimer's disease, unspecified	Pneumonia, unspecified	Heart failure, unspecified	Parkinson's disease	Malignant neoplasm of prostate	Alzheimer's disease, unspecified
12	Parkinson's disease	Chronic obstructive pulmonary disease with acute lower respiratory infection	Atrial fibrillation and atrial flutter, unspecified	Hypertensive heart disease with (congestive) heart failure	Malignant neoplasm of rectum	Stroke, not specified as haemorrhage or infarction
13	Malignant neoplasm of rectosigmoid junction	Parkinson's disease	Alcoholic cirrhosis of liver	Alcoholic cirrhosis of liver	Pancreas, unspecified	Parkinson's disease
14	Chronic obstructive pulmonary disease with acute lower respiratory infection	Bladder, unspecified	Mental and behavioural disorders due to use of alcohol, dependence syndrome	Colon, unspecified	Intracerebral haemorrhage, unspecified	Pancreas, unspecified
15	Malignant melanoma of skin, unspecified	Alzheimer's disease, unspecified	Chronic obstructive pulmonary disease with acute exacerbation, unspecified	Stroke, not specified as haemorrhage or infarction	Acute ischaemic heart disease, unspecified	Chronic obstructive pulmonary disease with acute lower respiratory infection
16	Other ill-defined and unspecified causes of mortality	Oesophagus, unspecified	Malignant neoplasm, unspecified	Atrial fibrillation and atrial flutter, unspecified	Intentional self-harm by hanging, strangulation and suffocation, home	Bladder, unspecified
17	Oesophagus, unspecified	Intentional self-harm by hanging, strangulation and suffocation	Pancreas, unspecified	Unspecified fall	Oesophagus, unspecified	Cardiac arrest, unspecified
18	Unspecified fall, unspecified place	Chronic ischaemic heart disease, unspecified	Atherosclerotic heart disease	Malignant neoplasm of rectum	Interstitial pulmonary disease, unspecified	Liver cell carcinoma
19	Pneumonia, unspecified	Congestive heart failure	Malignant neoplasm of rectum	Unattended death	Chronic renal failure, unspecified	Colon, unspecified
20	Bladder, unspecified	Other interstitial pulmonary diseases with fibrosis	Bacterial pneumonia, unspecified	Chronic obstructive pulmonary disease with acute lower respiratory infection	Other ill-defined and unspecified causes of mortality	Alcoholic cirrhosis of liver

Table 4 continued

## FEMALES

Rank	Australia	Canada	Denmark	Germany	Japan	Switzerland
1	Unspecified dementia	Unspecified dementia	Unspecified dementia	Atherosclerotic heart disease	Senility	Unspecified dementia
2	Acute myocardial infarction, unspecified	Bronchus or lung, unspecified	Other ill-defined and unspecified causes of mortality	Unspecified dementia	Pneumonia, unspecified	Chronic ischaemic heart disease, unspecified
3	Bronchus or lung, unspecified	Atherosclerotic heart disease	Bronchus or lung, unspecified	Heart failure, unspecified	Heart failure, unspecified	Breast, unspecified
4	Chronic ischaemic heart disease, unspecified	Acute myocardial infarction, unspecified	Stroke, not specified as haemorrhage or infarction	Breast, unspecified	Bronchus or lung, unspecified	Alzheimer's disease, unspecified
5	Stroke, not specified as haemorrhage or infarction	Breast, unspecified	Senility	Bronchus or lung, unspecified	Pneumonitis due to food and vomit	Bronchus or lung, unspecified
6	Breast, unspecified	Stroke, not specified as haemorrhage or infarction	Breast, unspecified	Acute myocardial infarction, unspecified	Sequelae of cerebral infarction	Other ill-defined and unspecified causes of mortality
7	Alzheimer's disease, unspecified	Alzheimer's disease, unspecified	Chronic obstructive pulmonary disease, unspecified	Hypertensive heart disease with (congestive) heart failure	Cerebral infarction, unspecified	Stroke, not specified as haemorrhage or infarction
8	Chronic obstructive pulmonary disease, unspecified	Chronic obstructive pulmonary disease, unspecified	Chronic obstructive pulmonary disease with acute lower respiratory infection	Atrial fibrillation and atrial flutter, unspecified	Acute myocardial infarction, unspecified	Heart failure, unspecified
9	Atrial fibrillation and atrial flutter, unspecified	Pneumonia, unspecified	Acute myocardial infarction, unspecified	Stroke, not specified as haemorrhage or infarction	Stomach, unspecified	Unspecified fall, unspecified place
10	Pancreas, unspecified	Colon, unspecified	Overlapping lesion of breast	Chronic obstructive pulmonary disease, unspecified	Breast, unspecified	Acute myocardial infarction, unspecified
11	Congestive heart failure	Pancreas, unspecified	Atrial fibrillation and atrial flutter, unspecified	Pneumonia, unspecified	Pancreas, unspecified	Pneumonia, unspecified
12	Pneumonia, unspecified	Malignant neoplasm of ovary	Chronic obstructive pulmonary disease with acute exacerbation, unspecified	Other ill-defined and unspecified causes of mortality	Congestive heart failure	Hypertensive heart disease with (congestive) heart failure
13	Unspecified fall, unspecified place	Atrial fibrillation and atrial flutter, unspecified	Malignant neoplasm of ovary	Pancreas, unspecified	Liver cell carcinoma	Essential (primary) hypertension
14	Malignant neoplasm of ovary	Congestive heart failure	Alzheimer's disease with late onset	Unspecified fall	Chronic renal failure, unspecified	Hypertensive heart disease without (congestive) heart failure
15	Chronic obstructive pulmonary disease with acute lower respiratory infection	Chronic obstructive pulmonary disease with acute lower respiratory infection	Malignant neoplasm, unspecified	Malignant neoplasm of ovary	Intracerebral haemorrhage, unspecified	Chronic obstructive pulmonary disease, unspecified
16	Malignant neoplasm of rectosigmoid junction	Other ill-defined and unspecified causes of mortality	Heart failure, unspecified	Colon, unspecified	Unspecified dementia	Pancreas, unspecified
17	Atherosclerotic heart disease	Unspecified fall	Overlapping lesion of bronchus and lung	Aortic (valve) stenosis	Acute ischaemic heart disease, unspecified	Malignant neoplasm of ovary
18	Septicaemia, unspecified	Malignant neoplasm, primary site unknown, so stated	Atherosclerotic heart disease	Essential (primary) hypertension	Atrial fibrillation and atrial flutter, unspecified	Cardiac arrest, unspecified
19	Heart failure, unspecified	Chronic ischaemic heart disease, unspecified	Alzheimer's disease, unspecified	Parkinson's disease	Colon, unspecified	Senility
20	Colon, unspecified	Parkinson's disease	Colon, unspecified	Cerebral infarction, unspecified	Septicaemia, unspecified	Endocarditis, valve unspecified

Red = Garbage codes with very high, high, medium impact and thus considered "unusable". Orange = Garbage codes with low impact and thus considered "insufficiently specified"

**Table 5** Top unusable codes as % of total garbage codes

ICD code	Cause of death	No. of deaths	% of all garbage
<i>Australia 2016</i>			
I50.0	Congestive heart failure	1.748	5.0
A41.9	Septicaemia, unspecified	1.485	4.3
C80.9	Malignant neoplasm, unspecified	1.320	3.8
C80.0	Malignant neoplasm, primary site unknown, so stated	1.234	3.5
I50.9	Heart failure, unspecified	1.127	3.2
C26.0	Intestinal tract, part unspecified	1.049	3.0
R99.-	Other ill-defined and unspecified causes of mortality	1.043	3.0
<i>Canada 2016</i>			
R99.-	Other ill-defined and unspecified causes of mortality	3.969	6.8
I50.0	Congestive heart failure	3.055	5.2
C80.0	Malignant neoplasm, primary site unknown	2.251	3.8
I50.9	Heart failure, unspecified	1.941	3.3
A41.9	Septicaemia, unspecified	1.716	2.9
X42.-	Accidental poisoning by and exposure to narcotics and psychodysleptics [hallucinogens], not elsewhere classified	1.462	2.5
<i>Denmark 2015</i>			
R99.-	Other ill-defined and unspecified causes of mortality	2.687	18.3
R54.-	Senility	835	5.7
I50.9	Heart failure, unspecified	685	4.7
<i>Germany 2016</i>			
I50.9	Heart failure, unspecified	33.259	14.2
R99.-	Other ill-defined and unspecified causes of mortality	18.368	7.8
I10.-	Essential (primary) hypertension	7.078	3.0
<i>Japan 2015</i>			
R54.-	Senility	84.810	18.4
I50.9	Heart failure, unspecified	58.240	12.7
<i>Switzerland 2015</i>			
R99.-	Other ill-defined and unspecified causes of mortality	2.125	12.8
I50.9	Heart failure, unspecified	1.407	8.5
I10.-	Essential (primary) hypertension	784	4.7

Cut-off for each country-specific listing was a cumulative % of total garbage codes of 25%. Australia, Canada, Denmark, Germany, Japan and Switzerland, 2015–2016

the use of the R99 code “Other ill-defined and unspecified deaths”, it is of concern when this cause appears among the leading causes. The same can be said for “Unspecified heart failure”, which is an intermediary COD and which accounts for between 3 and 14% of the garbage codes in the six countries examined. Rather, physicians should specify the underlying cause that led to death, which in the case of heart failure could, among others, be myocardial infarction, chronic renal failure, cerebrovascular accident, poisoning and haemorrhage.

Decreasing the proportion of deaths that are of no or little policy value should be a priority for all country health information systems. This assessment and analysis have shown that it is possible for health authorities to quickly obtain insight into the quality problems and certification

errors in the data, which can assist them to take corrective action. The results of the analysis reveal the main certification errors committed by doctors and identify the CODs that introduce bias into the leading causes of death. As demonstrated, the quantity, severity and type of garbage codes appearing in the national cause of death data vary across countries, suggesting that certification problems and coding may be somewhat culture specific. Identifying the specific garbage codes that produce the most unusable data in each country is an essential first step so that strategies can be tailored and developed to determine effective ways to train or inform certifiers. This will help certifiers to be more specific when they complete medical death certificates and to avoid committing errors that lead to garbage codes. Being aware of quality problems in the data can also



assist the authorities responsible for publishing the COD data to provide the explanations needed to correctly interpret the statistics. For instance, in Australia the government agency that publishes the COD data is careful to add the poisoning agent when it publishes data on the accidental poisoning garbage codes such as X42 and X44, thus increasing the information content of the data for policy that normally would be missing from these garbage codes.

National COD data represent a compilation of data from different geographic areas and health facilities, which may vary in their death certification practices, and hence accuracy. It is therefore advisable that countries undertake subnational assessments to verify how certification practices vary and tailor intervention strategies accordingly with more local approaches. For instance, lack of certain diagnostic imaging and analysis and under-staffing can lead to less-than-optimal medical records and make it even more challenging to correctly certify the COD.

Undertaking this type of assessment and communicating the findings to health authorities and medical associations will result in greater awareness of the need to pay more attention to the quality of medical certification. Medical schools in all six countries should give higher priority to the certification duty of their profession, and correct medical certification certainly should be included as a compulsory element of the induction programs for interns. Doctors perform a very important public health function in documenting the COD of their patients, not only for the families of the deceased, but also for society. They are generally unaware of this, or of its importance for public policy. Without reliable and detailed information on the leading CODs, and how they are changing, health planning and policy will be less cost-effective than otherwise might be the case, potentially resulting in lost opportunities to improve population health.

While ANACONDA cannot verify whether the physician diagnosed the correct COD or whether a COD was miscoded, it can detect whether the code assigned is a valid underlying cause and whether the certifier originally completed the death certificate according to ICD guidance. Adopting the ICD classification without adhering to its rules and standards for coding and guidance for certification will not provide good-quality COD information for public health use. This study has demonstrated that even for countries with very advanced health information systems, it is very informative to undertake an assessment of the COD data as the information content may be reduced by a high proportion of unusable and insufficiently specified causes.

Once the data have been evaluated and the specific problems revealed, focused action should be taken to reduce the amount of garbage codes by, for example,

introducing certification training for hospital interns and awareness raising in the medical community of the important functions of the death certificate for the national health information system. The large and complex bureaucracy that all countries have established to collect these data needs to meet the demands of increasingly sophisticated and complex health systems and provide them with the detailed information required for avoiding premature deaths and keeping people alive and healthy for as long as possible.

**Funding** Funding was provided by Melbourne Research, University of Melbourne.

## Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

**Ethical approval** This article does not contain any studies with human participants or animals performed by any of the authors.

**Informed consent** No data were collected from individual participants from whom informed consent would be required.

## References

- Adair T, Kippen R, Naghavi M, Lopez AD (2019) The setting of the rising sun? A recent comparative history of life expectancy trends in Japan and Australia. *PLoS ONE* 14(3):e0214578. <https://doi.org/10.1371/journal.pone.0214578>
- AIHW (2018) Australia's health 2018, Australian Institute of Health and Welfare 2018. Australia's health series no. 16. AUS 221. AIHW, Canberra. <https://www.aihw.gov.au/getmedia/7c42913d-295f-4bc9-9c24-4e44eff4a04a/aihw-aus-221.pdf.aspx?inline=true>
- Alpérovitch A, Bertrand M, Jouglu E, Vidal J-S, Ducimetière P, Helmer C et al (2009) Do we really know the cause of death of the very old? Comparison between official mortality statistics and cohort study classification. *Eur J Epidemiol* 24(11):669–675
- Chammartin F, Probst-Hensch N, Utzinger J, Vounatsou P (2016) Mortality atlas of the main causes of death in Switzerland, 2008–2012. *Swiss Med Wkly* 146:14280
- Civil Registration and Vital Statistics Knowledge Gateway. [https://crvsgateway.info/search-filter?s\\_q\\_fulltext=ANACONDA](https://crvsgateway.info/search-filter?s_q_fulltext=ANACONDA)
- ICD-11 Reference Guide (2019). <https://icd.who.int/icd11refguide/en/index.html>
- Lopez AD (2013) Reducing risks to health: what can we learn from the Global Burden of Disease 2010 Study? *Int J Public Health* 58(5):645–646
- Mahapatra P, Shibuya K, Lopez AD, Coullare F, Notzon F, Rao C, Sretzer S (2007) Civil registration systems and vital statistics: successes and missed opportunities. *Lancet* 370:1653–1663
- Mikkelsen et al (2015) Counting births and deaths 3—a global assessment of civil registration and vital statistics systems: monitoring data quality and progress. *Lancet* 386:1395–1406

- Mikkelsen L, Moesgaard K, Hegnauer M, Lopez AD (2020) ANACONDA: a new tool to improve mortality and cause of death data. *BMC Med*
- Murray CJL, Lopez AD (eds) (1996) *The Global Burden of Disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Global Burden of Disease and Injury Series, vol I.* Harvard University Press on behalf of the World Health Organization and The World Bank, Cambridge, MA
- Murray CJL et al (2018) Population and fertility by age and sex for 195 countries and territories 1950–2017: a systematic analysis for the Global Burden of Disease 2017. *Lancet* 392:1995–2051
- Naghavi M (2020) Improving the quality of death data for public health policy: are all ‘garbage’ codes equally problematic? *BMC Med*
- Naghavi M, Makela S, Foreman K, O’Brien J, Pourmalek F, Lozano R (2010) Algorithms for enhancing public health utility of national causes-of-death data. *Popul Health Metr* 8:9
- Philips DE, Lozano R, Naghavi M, Atkinson C, Gonzales-Medina D, Mikkelsen L, Murray CJL, Lopez AD (2014) A composite metric for assessing data on mortality and causes of death: the Vital Statistics Performance Index. *Popul Health Metr* 12:14
- Rampatige R, Mikkelsen L, Hernandez B, Lopez AD (2014) Hospital cause-of-death statistics: what should we make of them? *Bull World Health Organ* 92:3–3A. <https://doi.org/10.2471/BLT.13.134106>
- Roth GA, Dwyer-Lindgren L (2017) Trends and patterns of geographic variation in cardiovascular mortality among US counties, 1980–2014. *JAMA* 317(19):1976–1992. <https://doi.org/10.1001/jama.2017.4150>
- Roth GA et al (2018) Global, regional, and national age-sex-specific mortality for 282 causes of death, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 392:1736–1788
- Schdev A et al (2001) Problems with proper completion and accuracy of the cause-of-death statement. *Arch Intern Med* 161:277–284
- Shibuya K (2006) Counting the death is essential for health. *Bull WHO* 84(3):161–256
- World Health Organization (2016) *International statistical classification of diseases and related health problems, 10th revision, vol 2, 5th edn.* World Health Organization, Geneva
- WHO Mortality Database. CoDQL cause of death query online. [http://apps.who.int/healthinfo/statistics/mortality/causeofdeath\\_query/](http://apps.who.int/healthinfo/statistics/mortality/causeofdeath_query/)
- Wang H, Naghavi M, Allen C, Lopez AD, Murray CJL (2016) Global, regional, and national life expectancy, all-cause specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the global Burden of Disease Study 2015. *Lancet* 388:1459–544

**Publisher’s Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

## Affiliations

Lene Mikkelsen<sup>1</sup> · Kim Moesgaard Iburg<sup>2</sup> · Tim Adair<sup>1</sup> · Thomas Fürst<sup>3</sup> · Michael Hegnauer<sup>3</sup> · Elena von der Lippe<sup>4</sup> · Lauren Moran<sup>5</sup> · Shuhei Nomura<sup>6</sup> · Haruka Sakamoto<sup>6</sup> · Kenji Shibuya<sup>7</sup> · Annelene Wengler<sup>4</sup> · Stephanie Willbond<sup>8</sup> · Patricia Wood<sup>8</sup> · Alan D. Lopez<sup>1</sup> 

✉ Alan D. Lopez  
alan.lopez@unimelb.edu.au

Lene Mikkelsen  
l.mikkelsen@unimelb.edu.au

Kim Moesgaard Iburg  
kmi@ph.au.dk

Tim Adair  
timothy.adair@unimelb.edu.au

Thomas Fürst  
thomas.fuerst@swisstph.ch

Michael Hegnauer  
michael.hegnauer@swisstph.ch

Elena von der Lippe  
vonderLippeE@rki.de

Lauren Moran  
lauren.moran@abs.gov.au

Shuhei Nomura  
nom3.shu@gmail.com

Haruka Sakamoto  
harukask1231@gmail.com

Kenji Shibuya  
kenjishibuya1@gmail.com

Annelene Wengler  
WenglerA@rki.de

Stephanie Willbond  
stephanie.willbond@canada.ca

Patricia Wood  
patricia.wood@canada.ca

<sup>1</sup> Bloomberg Data for Health Initiative, University of Melbourne, Melbourne, Australia

<sup>2</sup> Institute of Public Health, Aarhus University, Århus, Denmark

<sup>3</sup> Swiss Tropical and Public Health Institute, Basel, Switzerland

<sup>4</sup> Department of Epidemiology and Health Monitoring, Robert Koch Institute, Berlin, Germany

<sup>5</sup> Australian Bureau of Statistics, Canberra, Australia

<sup>6</sup> Department of Global Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

<sup>7</sup> University Institute of Population Health, King’s College London, London, UK

<sup>8</sup> Statistics Canada, Ottawa, Canada

令和2年5月25日

厚生労働大臣  
—(国立医薬品食品衛生研究所長)—殿  
—(国立保健医療科学院長)—

機関名 国立大学  
所属研究機関長 職名 総長  
氏名 五神 勇

次の職員の令和元年度厚生労働科学研究費の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

1. 研究事業名 地球規模保健課題解決推進のための行政施策に関する研究事業
2. 研究課題名 我が国の世界保健総会等における効果的なプレゼンスの確立に関する研究
3. 研究者名 (所属部局・職名) 大学院医学系研究科・客員研究員  
(氏名・フリガナ) 渋谷 健司 シブヤケンジ

4. 倫理審査の状況

	該当性の有無		左記で該当がある場合のみ記入 (※1)		
	有	無	審査済み	審査した機関	未審査 (※2)
ヒトゲノム・遺伝子解析研究に関する倫理指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
遺伝子治療等臨床研究に関する指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
人を対象とする医学系研究に関する倫理指針 (※3)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
その他、該当する倫理指針があれば記入すること (指針の名称: )	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>

(※1) 当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他 (特記事項)

(※2) 未審査の場合は、その理由を記載すること。

(※3) 廃止前の「疫学研究に関する倫理指針」や「臨床研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

5. 厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 <input checked="" type="checkbox"/> 未受講 <input type="checkbox"/>
-------------	---

6. 利益相反の管理

当研究機関におけるCOIの管理に関する規定の策定	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合はその理由: )
当研究機関におけるCOI委員会設置の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合は委託先機関: )
当研究に係るCOIについての報告・審査の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合はその理由: )
当研究に係るCOIについての指導・管理の有無	有 <input type="checkbox"/> 無 <input checked="" type="checkbox"/> (有の場合はその内容: )

(留意事項) ・該当する□にチェックを入れること。  
・分担研究者の所属する機関の長も作成すること。

2020年 3月 31日

厚生労働大臣  
（国立医薬品食品衛生研究所長）殿  
（国立保健医療科学院長）

機関名 国立研究開発法人  
国立国際医療研究センター

所属研究機関長 職 名 理事長

氏 名 國土 典宏



次の職員の令和元年度厚生労働科学研究費の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

- 研究事業名 地球規模保健課題解決推進のための行政施策に関する研究事業
- 研究課題名 我が国の世界保健総会等における効果的なプレゼンスの確立に関する研究
- 研究者名 （所属部局・職名） 国際医療協力局 運営企画部長  
（氏名・フリガナ） 明石 秀親 ・ アカシ ヒデチカ

4. 倫理審査の状況

	該当性の有無		左記で該当がある場合のみ記入（※1）		
	有	無	審査済み	審査した機関	未審査（※2）
ヒトゲノム・遺伝子解析研究に関する倫理指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
遺伝子治療等臨床研究に関する指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
人を対象とする医学系研究に関する倫理指針（※3）	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
その他、該当する倫理指針があれば記入すること （指針の名称： ）	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>

（※1）当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他（特記事項）

（※2）未審査の場合は、その理由を記載すること。

（※3）廃止前の「疫学研究に関する倫理指針」や「臨床研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

5. 厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 <input checked="" type="checkbox"/> 未受講 <input type="checkbox"/>
-------------	---

6. 利益相反の管理

当研究機関におけるCOIの管理に関する規定の策定	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> （無の場合はその理由： ）
当研究機関におけるCOI委員会設置の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> （無の場合は委託先機関： ）
当研究に係るCOIについての報告・審査の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> （無の場合はその理由： ）
当研究に係るCOIについての指導・管理の有無	有 <input type="checkbox"/> 無 <input checked="" type="checkbox"/> （有の場合はその内容： ）

（留意事項） ・該当する□にチェックを入れること。  
・分担研究者の所属する機関の長も作成すること。

令和2年 3月 31日

厚生労働大臣  
（国立医薬品食品衛生研究所長）殿  
（国立保健医療科学院長）

機関名 国立研究開発法人  
国立国際医療研究センター  
所属研究機関長 職名 理事長  
氏名 國土 典宏 印



次の職員の令和元年度厚生労働科学研究費の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

- 研究事業名 地球規模保健課題解決推進のための行政施策に関する研究事業
- 研究課題名 我が国の世界保健総会等における効果的なプレゼンスの確立に関する研究
- 研究者名 （所属部局・職名） 国際医療協力局・人材開発部長  
（氏名・フリガナ） 三好知明・ミヨシチアキ

#### 4. 倫理審査の状況

	該当性の有無		左記で該当がある場合のみ記入（※1）		
	有	無	審査済み	審査した機関	未審査（※2）
ヒトゲノム・遺伝子解析研究に関する倫理指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
遺伝子治療等臨床研究に関する指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
人を対象とする医学系研究に関する倫理指針（※3）	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
その他、該当する倫理指針があれば記入すること （指針の名称： )	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>

（※1）当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他（特記事項）

（※2）未審査の場合は、その理由を記載すること。

（※3）廃止前の「疫学研究に関する倫理指針」や「臨床研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

#### 5. 厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 <input checked="" type="checkbox"/> 未受講 <input type="checkbox"/>
-------------	---

#### 6. 利益相反の管理

当研究機関におけるCOIの管理に関する規定の策定	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> （無の場合はその理由： )
当研究機関におけるCOI委員会設置の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> （無の場合は委託先機関： )
当研究に係るCOIについての報告・審査の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> （無の場合はその理由： )
当研究に係るCOIについての指導・管理の有無	有 <input type="checkbox"/> 無 <input checked="" type="checkbox"/> （有の場合はその内容： )

（留意事項） ・該当する□にチェックを入れること。  
・分担研究者の所属する機関の長も作成すること。

2020年 5月 8日

厚生労働大臣  
—(国立医薬品食品衛生研究所長)— 殿  
—(国立保健医療科学院長)—

機関名 国立大学  
所属研究機関長 職 名 総長  
氏 名 五神 眞 郎

次の職員の令和元年度厚生労働科学研究費の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

1. 研究事業名 地球規模保健課題解決推進のための行政施策に関する研究事業
2. 研究課題名 我が国の世界保健総会等における効果的なプレゼンスの確立に関する研究
3. 研究者名 (所属部局・職名) 大学院医学系研究科・特任助教  
(氏名・フリガナ) 野村 周平 ノムラシュウヘイ

4. 倫理審査の状況

	該当性の有無		左記で該当がある場合のみ記入(※1)		
	有	無	審査済み	審査した機関	未審査(※2)
ヒトゲノム・遺伝子解析研究に関する倫理指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
遺伝子治療等臨床研究に関する指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
人を対象とする医学系研究に関する倫理指針(※3)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
その他、該当する倫理指針があれば記入すること (指針の名称: )	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>

(※1) 当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他(特記事項)

(※2) 未審査の場合は、その理由を記載すること。

(※3) 廃止前の「疫学研究に関する倫理指針」や「臨床研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

5. 厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 <input checked="" type="checkbox"/> 未受講 <input type="checkbox"/>
-------------	---

6. 利益相反の管理


当研究機関におけるCOIの管理に関する規定の策定	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合はその理由: )
当研究機関におけるCOI委員会設置の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合は委託先機関: )
当研究に係るCOIについての報告・審査の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合はその理由: )
当研究に係るCOIについての指導・管理の有無	有 <input type="checkbox"/> 無 <input checked="" type="checkbox"/> (有の場合はその内容: )

(留意事項) ・該当する□にチェックを入れること。  
・分担研究者の所属する機関の長も作成すること。

令和 2 年 4 月 10 日

厚生労働大臣  
(国立医薬品食品衛生研究所長) 殿  
(国立保健医療科学院長)

機関名 国立研究開発法人国立がん研究センター  
所属研究機関長 職 名 理事長  
氏 名 中釜 斉



次の職員の令和元年度厚生労働科学研究費の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

1. 研究事業名 地球規模保健課題解決推進のための行政施策に関する研究事業
2. 研究課題名 我が国の世界保健総会等における効果的なプレゼンスの確立に関する研究
3. 研究者名 (所属部局・職名) 社会と健康研究センター予防研究部・研究員  
(氏名・フリガナ) 阿部 サラ・アベ サラ

#### 4. 倫理審査の状況

	該当性の有無		左記で該当がある場合のみ記入 (※1)		
	有	無	審査済み	審査した機関	未審査 (※2)
ヒトゲノム・遺伝子解析研究に関する倫理指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
遺伝子治療等臨床研究に関する指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
人を対象とする医学系研究に関する倫理指針 (※3)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
その他、該当する倫理指針があれば記入すること (指針の名称: )	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>

(※1) 当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他 (特記事項)

(※2) 未審査の場合は、その理由を記載すること。

(※3) 廃止前の「疫学研究に関する倫理指針」や「臨床研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

#### 5. 厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 <input checked="" type="checkbox"/> 未受講 <input type="checkbox"/>
-------------	---

#### 6. 利益相反の管理

当研究機関におけるCOIの管理に関する規定の策定	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合はその理由: )
当研究機関におけるCOI委員会設置の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合は委託先機関: )
当研究に係るCOIについての報告・審査の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合はその理由: )
当研究に係るCOIについての指導・管理の有無	有 <input type="checkbox"/> 無 <input checked="" type="checkbox"/> (有の場合はその内容: )

(留意事項) ・該当する□にチェックを入れること。  
・分担研究者の所属する機関の長も作成すること。

2020年 5月 8日

厚生労働大臣  
—(国立医薬品食品衛生研究所長)— 殿  
—(国立保健医療科学院長)—

機関名 国立大学

所属研究機関長 職 名 総長

氏 名 五神 真

次の職員の令和元年度厚生労働科学研究費の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

1. 研究事業名 地球規模保健課題解決推進のための行政施策に関する研究事業
2. 研究課題名 我が国の世界保健総会等における効果的なプレゼンスの確立に関する研究
3. 研究者名 (所属部局・職名) 大学院医学系研究科・助教  
(氏名・フリガナ) ラハマン・ミジャヌール

4. 倫理審査の状況

	該当性の有無		左記で該当がある場合のみ記入 (※1)		
	有	無	審査済み	審査した機関	未審査 (※2)
ヒトゲノム・遺伝子解析研究に関する倫理指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
遺伝子治療等臨床研究に関する指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
人を対象とする医学系研究に関する倫理指針 (※3)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
その他、該当する倫理指針があれば記入すること (指針の名称: )	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>

(※1) 当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他 (特記事項)

(※2) 未審査に場合は、その理由を記載すること。

(※3) 廃止前の「疫学研究に関する倫理指針」や「臨床研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

5. 厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 <input checked="" type="checkbox"/> 未受講 <input type="checkbox"/>
-------------	---

6. 利益相反の管理

当研究機関におけるCOIの管理に関する規定の策定	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合はその理由: )
当研究機関におけるCOI委員会設置の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合は委託先機関: )
当研究に係るCOIについての報告・審査の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合はその理由: )
当研究に係るCOIについての指導・管理の有無	有 <input type="checkbox"/> 無 <input checked="" type="checkbox"/> (有の場合はその内容: )

(留意事項) ・該当する□にチェックを入れること。  
・分担研究者の所属する機関の長も作成すること。



2020年 5月 8日

厚生労働大臣  
—(国立医薬品食品衛生研究所長)— 殿  
—(国立保健医療科学院長)—

機関名 国立大学

所属研究機関長 職 名 総長

氏 名 五神 真

次の職員の令和元年度厚生労働科学研究費の調査研究における、倫理審査状況及び管理については以下のとおりです。

1. 研究事業名 地球規模保健課題解決推進のための行政施策に関する研究事業
2. 研究課題名 我が国の世界保健総会等における効果的なプレゼンスの確立に関する研究
3. 研究者名 (所属部局・職名) 大学院医学系研究科・特任研究員  
(氏名・フリガナ) 坂元 晴香 サカモトハルカ

4. 倫理審査の状況

	該当性の有無		左記で該当がある場合のみ記入 (※1)		
	有	無	審査済み	審査した機関	未審査 (※2)
ヒトゲノム・遺伝子解析研究に関する倫理指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
遺伝子治療等臨床研究に関する指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
人を対象とする医学系研究に関する倫理指針 (※3)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
その他、該当する倫理指針があれば記入すること (指針の名称: )	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>

(※1) 当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他 (特記事項)

(※2) 未審査に場合は、その理由を記載すること。

(※3) 廃止前の「疫学研究に関する倫理指針」や「臨床研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

5. 厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 <input checked="" type="checkbox"/> 未受講 <input type="checkbox"/>
-------------	---

6. 利益相反の管理


当研究機関におけるCOIの管理に関する規定の策定	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合はその理由: )
当研究機関におけるCOI委員会設置の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合は委託先機関: )
当研究に係るCOIについての報告・審査の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合はその理由: )
当研究に係るCOIについての指導・管理の有無	有 <input type="checkbox"/> 無 <input checked="" type="checkbox"/> (有の場合はその内容: )

(留意事項) ・該当する□にチェックを入れること。  
・分担研究者の所属する機関の長も作成すること。

令和2年 4 月 1 日

厚生労働大臣  
(国立医薬品食品衛生研究所長) 殿  
(国立保健医療科学院長)

機関名 国立研究開発法人国立がん研究センター  
所属研究機関長 職名 理事長  
氏名 中釜 齊



次の職員の令和元年度厚生労働科学研究費の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

- 研究事業名 地球規模保健課題解決推進のための行政施策に関する研究事業
- 研究課題名 我が国の世界保健総会等における効果的なプレゼンスの確立に関する研究
- 研究者名 (所属部局・職名) がん対策情報センター がん統計・総合解析研究部  
(氏名・フリガナ) 齋藤英子 サイトウエイコ

#### 4. 倫理審査の状況

	該当性の有無		左記で該当がある場合のみ記入 (※1)		
	有	無	審査済み	審査した機関	未審査 (※2)
ヒトゲノム・遺伝子解析研究に関する倫理指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
遺伝子治療等臨床研究に関する指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
人を対象とする医学系研究に関する倫理指針 (※3)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
その他、該当する倫理指針があれば記入すること (指針の名称: )	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>

(※1) 当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他 (特記事項)

(※2) 未審査の場合は、その理由を記載すること。

(※3) 廃止前の「疫学研究に関する倫理指針」や「臨床研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

#### 5. 厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 <input checked="" type="checkbox"/> 未受講 <input type="checkbox"/>
-------------	---

#### 6. 利益相反の管理

当研究機関におけるCOIの管理に関する規定の策定	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合はその理由: )
当研究機関におけるCOI委員会設置の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合は委託先機関: )
当研究に係るCOIについての報告・審査の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合はその理由: )
当研究に係るCOIについての指導・管理の有無	有 <input type="checkbox"/> 無 <input checked="" type="checkbox"/> (有の場合はその内容: )

(留意事項) ・該当する□にチェックを入れること。  
・分担研究者の所属する機関の長も作成すること。

2020年 5月 8日

厚生労働大臣  
~~(国立医薬品食品衛生研究所長)~~ 殿  
~~(国立保健医療科学院長)~~

機関名 国立大学

所属研究機関長 職 名 総長

氏 名 五神 真

次の職員の令和元年度厚生労働科学研究費の調査研究における、倫理審査状況及び利益相反等の管理については以下のとおりです。

- 1. 研究事業名 地球規模保健課題解決推進のための行政施策に関する研究事業
- 2. 研究課題名 我が国の世界保健総会等における効果的なプレゼンスの確立に関する研究
- 3. 研究者名 (所属部局・職名) 大学院医学系研究科・客員研究員  
(氏名・フリガナ) 米岡 大輔 ヨネオカダイスケ

4. 倫理審査の状況

	該当性の有無		左記で該当がある場合のみ記入 (※1)		
	有	無	審査済み	審査した機関	未審査 (※2)
ヒトゲノム・遺伝子解析研究に関する倫理指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
遺伝子治療等臨床研究に関する指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
人を対象とする医学系研究に関する倫理指針 (※3)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
厚生労働省の所管する実施機関における動物実験等の実施に関する基本指針	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>
その他、該当する倫理指針があれば記入すること (指針の名称: )	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>		<input type="checkbox"/>

(※1) 当該研究者が当該研究を実施するに当たり遵守すべき倫理指針に関する倫理委員会の審査が済んでいる場合は、「審査済み」にチェックし一部若しくは全部の審査が完了していない場合は、「未審査」にチェックすること。

その他 (特記事項)

(※2) 未審査の場合は、その理由を記載すること。

(※3) 廃止前の「疫学研究に関する倫理指針」や「臨床研究に関する倫理指針」に準拠する場合は、当該項目に記入すること。

5. 厚生労働分野の研究活動における不正行為への対応について

研究倫理教育の受講状況	受講 <input checked="" type="checkbox"/> 未受講 <input type="checkbox"/>
-------------	---

6. 利益相反の管理

当研究機関におけるCOIの管理に関する規定の策定	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合はその理由: )
当研究機関におけるCOI委員会設置の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合は委託先機関: )
当研究に係るCOIについての報告・審査の有無	有 <input checked="" type="checkbox"/> 無 <input type="checkbox"/> (無の場合はその理由: )
当研究に係るCOIについての指導・管理の有無	有 <input type="checkbox"/> 無 <input checked="" type="checkbox"/> (有の場合はその内容: )

(留意事項) ・該当する□にチェックを入れること。  
・分担研究者の所属する機関の長も作成すること。

研究成果の刊行に関する一覧 無し